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Abstract
PAIN MANAGEMENT AND MENOPAUSAL HEALTH OUTCOMES IN MULTIPLE
SCLEROSIS
By Rachel Hannah Jawahar, MPH, PhD
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2013.
Major Director: Saba W. Masho, MD DrPH
Associate Professor,
Division of Epidemiology, Department of Family Medicine and Population Health

Background: Previous studies have addressed multiple sclerosis (MS) symptom
management and improved health-related quality of life (HrQOL). Yet lowered estrogen
levels in post-menopasual women with MS may further worsen physical function and
symptomology and not all types of pain management have been examined.
Objectives: For post-menopausal women with MS, we evaluated the extent to which
smoking is associated with worsened health outcomes and HrQOL, and the extent to
which menopausal hormone treatment (MHT) improves health outcomes and HrQOL.
For all adult men and women with clinically diagnosed MS, we systematically reviewed
pharmacological and non-pharmacological strategies for the reduction of pain.

Methods: We identified 256 post-menopausal women with MS in the Women's Health
Initiative Observational Study and examined changes from baseline to 3 years in
activities of daily living, physical activity, SF-36 mental and physical component scales
(MCS, PCS), and menopausal symptoms. In all adults, experimental studies published
after 1965 were included if the sample was not restricted to participants with spasticity
or trigeminal neuralgia and participant-reported pain was a primary or secondary
outcome. Pain scores were reported as Cohen’s d.
Results: Nine percent of post-menopausal women with MS were current smokers and
51% reported current MHT use. Smoking and MHT use had no effect on physical
functioning, activities of daily living, or menopausal symptoms. Women with early age
at smoking initiation experienced declines in MCS (adjusted β <20 vs. ≥ 25 years: 10.50, 95% Confidence Interval (CI) -2.1 to -18.1; adjusted β 20-24 vs. ≥ 25 years: 8.81, 95% CI: 0.6 to -17.4), but not in PCS. Relative to never MHT users, ever MHT
users had higher MCS scores at year 3 compared to baseline (adjusted β: 3.0, 95% CI:
0.4 to 5.6), but no change in PCS. For all adults, transcutaneous electrical nerve
stimulation (TENS; Cohen’s d: -3.34), nabixomols (Cohen’s d: -0.61), and
dextromethorphan/quinidine (Cohen’s d: -0.22) were reported effective in reducing pain.
Conclusions: Smoking prevention efforts should be increased for women with MS.
Women with MS may also experience HrQOL gains with MHT, but contemporaneous
data on MHT use is needed. TENS may be more effective than pharmacological
methods in reducing MS pain.

Chapter 1: Background

Multiple sclerosis (MS) is a chronic disease that affects nearly 2.5 million people
worldwide.1 The pathophysiology of the disease is still relatively unknown, but MS is
physically characterized by the presence of lesions (sites of demyelinated axonal
sheaths) in the CNS followed by partial or complete remyelination.2 Lesions have been
linked to ‘attacks,’ or episodes of neurological symptoms which persist for at least 24
hours.3 While the human body naturally regenerates myelin, this process may require
months1 and subsequent attacks during the healing period may impair recovery, leading
to more severe symptoms and functional disabilities.2
Using magnetic resonance imaging (MRI) evidence, MS is typically diagnosed by
the dissemination of lesions or attacks over time (at least 30 days between each onset)
and space (multiple lesions at once throughout the CNS).3 The three major types of MS
in order of frequency are relapsing-remitting (RRMS), primary progressive (PPMS),
secondary progressive (SPMS).4 RRMS is characterized by clearly defined relapses
(lesions or attacks) with full or partial recovery and a lack of disease progression.
Similarly, PPMS consists of alternating periods of relapses and partial recovery, but
relapses are accompanied by disease progression; this leads to steadily worsened
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disability over the lifespan. SPMS consists of an initial RRMS phase which later
worsens into steadily-increased disability with few to no relapses.
The lesions which characterize MS may present at any time in the lifespan, with
pediatric-onset (≤ 18 years of age)2 and late-onset MS (diagnosed at age ≥ 50 years)5
less common than adult-onset MS (diagnosed from 25 to 35 years of age).6 Similarly,
risk factors for MS can begin as early as birth, and behaviors throughout the lifespan
may increase future risk of MS diagnosis. Like other autoimmune diseases, the
strongest known risk factor for MS is family history; siblings of MS patients have 30
times greater risk of MS than others in the general population.6 Females are also at
greater risk for MS, as nearly two-thirds of all MS patients are women6 and women have
an earlier age of onset than men.2, 7
Risk factors which occur later in life are most likely to be modifiable. These
include environmental factors such as the latitude of residence and behavioral factors
such as vitamin D intake and smoking. Smoking has strong ties to MS incidence;
studies have linked past and current smoking to earlier age of MS onset8 and increased
pack-years to greater risk of MS.9, 10 Vitamin D insufficiency has been linked to greater
risk of MS;11 additionally, a higher incidence of MS at higher latitudes is thought to be
related to decreased sun exposure and decreased serum levels of vitamin D.12 In fact,
many of the modifiable risk factors mentioned above are also related to worsened
disease progression. MS patients who continue to smoke after diagnosis have been
shown to have faster rates of disability,13 while vitamin D insufficiency has been tied to
more frequent relapses in RRMS.14
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Because MS is a disease which originates in the central nervous system, the
health-related quality of life for MS patients is strongly influenced by symptomology.
Common symptoms include incontinence, pain, speech impairment, blurred vision, poor
sleep quality, and loss of mobility.15-18 Women with MS also experience hot flashes,19, 20
sexual dysfunction,21, 22 and vaginal dryness.23, 24 Most MS-specific therapies focus on
slowing disease progression, but few treatments are meant for MS-specific symptomatic
management. Thus, it is necessary to find new ways to manage symptoms and
improve health-related quality of life in MS patients over the lifespan.
This dissertation assesses pain management strategies for both men and women
with MS and symptomology and quality of life in post-menopausal women by: evaluating
the extent to which health outcomes are worsened for post-menopausal MS patients
who have ever smoked in comparison to MS patients who have never smoked;
estimating the extent to which ever menopausal hormone therapy use benefits the
health outcomes of post-menopausal women with MS in comparison to MS patients
who have never used hormone therapy; and systematically reviewing pain management
strategies for the reduction of non-spastic and non-trigeminal neuralgic pain in MS
patients;
By evaluating these outcomes in these particular subgroups, we seek to increase
understanding of previously-published literature on pain management strategies in MS
patients, while providing impetus for more randomized controlled trials and prospective
longitudinal studies in the future. Additionally, the questions answered in postmenopausal women with MS are the first in this important subpopulation; women in the
menopausal transition experience many of the symptoms listed above,25 indicating
3

worsened health-related quality of life for those women with MS who are also
experiencing menopause. Because the U.S. population is aging at an accelerated rate,
26

this research is intended to benefit future physician decisions regarding care for aging

patients with MS.
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Chapter 2: Association between Smoking and Health Outcomes in
Postmenopausal Women Living with Multiple Sclerosis
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Abstract
Background: Previous studies have addressed multiple sclerosis (MS) symptom
management and improved health-related quality of life (HrQOL) through modifiable risk
factors such as smoking.
Objective: Evaluate the extent to which smoking is associated with worsened health
outcomes and HrQOL for postmenopausal women with MS.
Methods: We identified 251 participants with MS in the Women's Health Initiative
Observational Study. Outcomes included changes from baseline to 3 years in in selfreported activities of daily living, physical activity, HrQOL mental and physical
component scales (MCS, PCS) of the SF-36, and menopausal symptoms.
Results: Nine percent of women were current and 50% past smokers. While never
smokers experienced declines in physical activity, current and past smokers maintained
their activity. Women with early age at smoking initiation experienced declines in MCS
(adjusted MCS β <20 vs. ≥ 25 years: -10.50, 95% Confidence Interval (CI) -2.1 to -18.1;
adjusted MCS β 20-24 vs. ≥ 25 years: -8.81, 95% CI: 0.6 to -17.4), but not in PCS. No
changes in menopausal symptoms were associated with smoking status.
Conclusion: No effects of smoking status were observed on changes in menopausal
symptoms. Regardless, women with MS should be encouraged to quit smoking
because young age at smoking initiation was associated with declining mental HrQOL
during menopause.
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Introduction
Multiple sclerosis (MS) is a chronic disease of the central nervous system whose
symptoms impact health-related quality of life (HrQOL) across the lifespan.15, 27 MS
disproportionately affects more women than men.6 Yet, the extent to which the
menopausal transition in women worsens MS symptoms remains largely unexplored.
Previous studies have addressed symptom management in MS through modifiable risk
factors such as smoking.28 It is known that 40%10, 13 of women with MS are current
smokers, yet it is unknown how smoking affects MS outcomes post-menopause.
In both menopausal and post-menopausal women, current smokers report
increased odds of vasomotor symptoms, hot flashes, forgetfulness,29 and worsened
HrQOL.30 In MS, smoking has been linked to increased incidence10 and faster MS
progression8, 13 leading to worse health outcomes.31 More than 37 million women are
approaching or experiencing menopause32 in a quickly aging U.S. population,26
indicating the need for greater focus on symptom management for women with MS
during the menopausal transition and beyond. Using a multi-center prospective study of
U.S. postmenopausal women, we aimed to evaluate the extent to which health
outcomes and HrQOL are worsened for MS patients who currently smoke or previously
smoked relative to never-smoking MS patients.

Methods
Participants
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The Women‘s Health Initiative Observation Study (WHI-OS), sponsored by the
National Institutes of Health and the National Heart, Lung, and Blood Institute, followed
93,676 racially diverse women ages 50 to 79 years who were recruited from 40 clinical
centers throughout the U.S.33 Women were eligible for participation in the WHI-OS if
they were post-menopausal, not enrolled in other WHI clinical trials, and unlikely to
relocate or die within 3 years. Protocols for WHI-OS were reviewed and approved by
human subjects review committees at each participating institution.34 Analyses included
251 WHI-OS participants with MS who completed baseline to year three assessments
and had complete exposure information by January 2013. Participants were considered
diagnosed with MS if they reported ‘yes’ when answering the question, "Has a doctor
ever told you you had MS?"
Determination of smoking status
Smoking status was determined from baseline self-report and was separated into
six cigarette smoking exposure variables. During the WHI data collection period,
participants were asked, “During your entire life, have you smoked at least 100
cigarettes?” Those who responded ‘yes’ were then asked, “Do you smoke cigarettes
now?” The responses to these questions were combined to indicate baseline smoking
status as ever (with separate categories for current or past use) or never smoker.
Current and past smokers were asked their ages at smoking initiation (<20 years, 20-24
years, 25 years and older), the number of cigarettes smoked per day (<15 cigarettes per
day, ≥ 15 cigarettes per day), and the number of years they smoked regularly (<30
years, ≥30 years). Past smokers were also asked their age at cessation (<40 years,
≥40 years of age). All categorizations were provided by the WHI. The number of
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smoking pack-years was calculated by multiplying the total years of smoking by the
number of cigarettes smoked per day divided by 20,35 and categorized as <10 packyears, 10-29 pack-years, and ≥30 pack-years.
Outcome ascertainment
We evaluated changes in three types of measures: health-related quality of life,
menopausal symptoms, and indicators of physical functioning and activity measures.
HrQOL was measured using the RAND 36-Item Health Survey (SF-36)36 which has
been validated in MS patients;37 for these analyses, we calculated the Mental
Component Score (MCS) and the Physical Component Score (PCS) for each
participant, each ranging from 0 to 100 points with 50 representing the mean score in
the general population. Scores below 50 indicated worse mental or physical health
relative to the general population.
A similar approach was used to evaluate changes in activities of daily living
(ADL) and physical activity. ADLs (modified from the original Katz38 index) consisted of
four separate items regarding the participant’s ability to eat, get in and out of bed, dress,
and/or take a bath on her own, and each item had three possible values (1=without
help, 2=some help, and 3=completely unable). For baseline and year 3, scores
(ranging from 4 to 12) were summed to represent overall ADLs with a lower score
indicating better health. Baseline ADL scores were subtracted from year 3 ADL scores
so that a positive change score represented a decline in ADLs. Physical activity was
computed from self-reported energy expenditures for recreational activities, including
walking and other mild/moderate/strenuous activity. These responses were scored as
total metabolic equivalent tasks (MET) hours per week. Previous studies in WHI
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participants have shown calculated MET hours per week are comparable to physical
activity diaries.39 Baseline scores were subtracted from year 3 scores such that a
positive change score indicated an increase in physical activity.
Based on menopause-specific symptoms adapted from the Postmenopausal
Estrogen/Progestin Interventions symptom tool,40 we considered the following to be
menopausal symptoms: forgetfulness, difficulty concentrating, mood swings, joint pain
or stiffness, headaches or migraines, breast tenderness, increased or decreased
appetite, hot flashes, night sweats, vaginal/genital irritation, and vaginal/genital dryness.
For each symptom, participants were asked how bothersome the symptom was in the
past four weeks (0=did not occur, 1= mild, 2=moderate, 3=severe). Each response was
collapsed into binary variables (0=did not occur, 1=symptom occurred (mild, moderate,
severe)). At baseline and year 3, a summary measure was constructed by adding the
number of symptoms reported (scores ranged from 0 to 11). We treated the outcome
as a continuous variable by subtracting the baseline sum from the year 3 summary
measure.
Potential Covariates
Potential confounders considered included years since menopause, alcohol use,
body mass index (BMI), menopausal hormone therapy (MHT) use, and vitamin D intake.
Years since menopause was calculated as the difference between youngest reported
age when menses ceased (age when participant experienced last menstruation,
oophorectomy, or initiated MHT) and reported age at baseline. Baseline alcohol use
was assessed using self-reported use and beer, wine, and liquor servings in the Food
Frequency Questionnaire (FFQ) and categorized as never, past, and current use.
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Baseline BMI was calculated in kg/m2 units from heights and weights measured with
calibrated balances and stadiometers. For these analyses, BMI was categorized
according to the 2012 World Health Organization guidelines: BMI <18.5 kg/m2 as
underweight, BMI between 18.5 kg/m2 and less than 25 kg/m2 as normal weight, 25
kg/m2 to less than 30 kg/m2 as overweight, and at least 30 kg/m2 as obese. Reported
baseline use of MHT (unopposed estrogen and/or estrogen plus progesterone) pills or
patches were recoded as current, past, or never use. Baseline vitamin D insufficiency
was defined as <800 IU by applying previously published cut points41 to data from the
FFQ and self-reported supplement use.
Statistical analysis
First we reported the sociodemographic (age, race/ethnicity, education, health
insurance status), clinical (years since menopause, BMI, alcohol use, MHT use, vitamin
D intake), and smoking characteristics (age started smoking, cigarettes smoked per
day, years smoked regularly, smoking pack-years, and age at smoking cessation) by
smoking status. Next, multivariable linear regression models were used to estimate
associations between differences in three-year HrQOL, ADL, and physical activity
scores and number of menopausal symptoms by baseline smoking status. When model
building, we examined univariate distributions of each score differences and years since
menopause to ensure normality. After examining missing values for determinants and
outcomes conditional on potential confounders, we determined missing data were
completely at random and would not produce biased estimates in these data.
Therefore, complete case analyses were used for each model. Multicollinearity was
ruled out by evaluating correlations between each potential confounder (e.g. years since
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menopause, alcohol use, BMI, MHT use, vitamin D intake). We used an iterative
approach to evaluate confounding. Variables whose addition to the model resulted in ≥
10% change in the estimate of association were considered confounders and retained
in the models. We also evaluated fully adjusted models which included all potential
confounders. Model fit was evaluated in several ways. We visually inspected residual
plots to ensure residuals were spaced around zero, confirming that a linear regression
was appropriate for these data. Normality was confirmed by visually inspecting Q-Q
plots for linearity. Outliers were not found when the studentized residuals were
examined. We provided beta coefficients and corresponding 95% confidence intervals
(CI) from the adjusted models. Statistical significance was determined using an alpha
level of 0.05.

Results
Of the 251 women in this sample, only 6% changed smoking status from
baseline measures to year 3. Nearly 9% of women were current smokers and 50.2%
were past smokers (Table 2.1). More current smokers (65.2%) than past smokers
(48.4%) were 59 years of age or younger at baseline. Most women identified as nonHispanic White regardless of smoking status. Of all non-Hispanic Blacks, 18.6% were
current smokers and 61.5% were past smokers. Regardless of smoking status, most
women had some college or higher education levels, health insurance, and were of
normal weight or underweight. While 81% of never smokers reported ever alcohol use,
83% of current and 80% of past smokers reported current alcohol use. At least half of
never smokers and 57% of current smokers reported MHT use while 48% of past
12

smokers reported MHT use. All women, regardless of smoking status, had less than
800 IU Vitamin D intake per day from food, over the counter supplements, and/or
prescribed supplements.
Most women began smoking at age 25 years of age or older and most reported
regularly smoking less than 15 cigarettes per day (Table 2.1). Seventy-five percent of
current smokers and 25% of past smokers reported regularly smoking for ≥ 30 years.
When converted to pack-years, 43% of current smokers and 23% of past smokers
smoked for 30 pack-years or more. Most past smokers reported quitting at age 40
years or older.
From baseline to year three of follow-up, greater changes in HrQOL were shown
in the MCS rather than PCS (Table 2.2). Age at smoking initiation was associated with
significant changes in MCS during menopause in patients with MS. Relative to women
who began smoking at ≥ 25 years of age, women who began smoking aged less than
20 years had lower MCS scores at year 3 compared to baseline (adjusted β: -10.50,
95% Confidence Interval (CI): -18.9 to -2.1). PCS scores were unchanged. Similarly,
women who began smoking at 20-24 years of age had lower MCS scores (adjusted β: 8.81, 95% CI: -18.1 to 0.4), but no change in PCS. No differences in change in MCS
scores were observed based on overall smoking status (current vs. past vs. never
smoker). Smoking pack-years were not associated with changes in PCS or MCS.
Interestingly, past smokers who reported quitting at age 40 years or older had higher
PCS scores (adjusted β: 3.43, 95% CI: -0.3 to 7.2) and lower MCS scores (adjusted β: 4.45, 95% CI: -9.2 to 0.3).
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Table 2.3 shows the association between various definitions of smoking and
change in ADLs and physical activity from baseline to year 3. From baseline to year 3,
the mean ADL change was 0.01 in never smokers and -0.02 in ever smokers. None of
the associations between ADL change and smoking were statistically significant. For
physical activity, women who reported never smoking experienced a decrease of 3.66
MET task hours per week in physical activity, former smokers a decline of 0.60, and
current smokers a decline of 0.10. Relative to women who never smoked, we observed
a slower decline in physical activity for current smokers (adjusted β: 4.15, 95% CI: -0.8
to 9.1) and former smokers (adjusted β: 3.48, 95% CI: 0.5 to 6.4) in physical activity.
The five most prevalent menopausal symptoms reported at baseline included
joint pain/stiffness (74%), forgetfulness (68%), difficulty concentrating (48%), headaches
(45%), mood swings (42%), and vaginal dryness (31%). Aside from joint pain (10%),
few ranked symptoms as severe. The least common menopausal symptom reported
was a decrease in appetite, regardless of smoking status or time point. Except for
vaginal dryness, these estimates were similar at year 3. Differences in change in
menopausal symptoms by overall smoking status were not observed (Table 2.4). On
average, women who reported never smoking experienced no mean change in
menopausal symptoms (0.01), while former smokers (0.37) and current smokers (0.48)
reported more symptoms in year 3 relative to baseline. Compared to women who
began smoking at age 25 years or older, increases in the number of menopausal
symptoms from baseline to year 3 were found for women who began smoking aged less
than 20 years (adjusted β: 2.94, 95% CI: 0.4 to 5.5) and for women who began smoking
between ages 20 to 24 (adjusted β: 3.27, 95% CI: 0.5 to 6.0). Women who smoked for
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30 pack-years or more experienced a reduction in menopausal symptoms than women
who smoked less than 10 pack-years (adjusted β: -2.75, 95% CI: -4.7 to -0.8).

Conclusions
To our knowledge, this is the first study to estimate the associations between
smoking status and outcomes in post-menopausal women living with MS. Nearly half of
all women with MS in the WHI-OS were past smokers, and most had ceased at age 40
years or older. Women with MS who began smoking at a young age had substantially
worse mental HrQOL at year 3 than at baseline, indicating a decline in cognition during
menopause for those who began smoking at age 20 years or younger. A similar trend in
change mental HrQOL during menopause was observed for women with MS who began
smoking between ages 20 to 24. Change in in physical HrQOL was not associated with
age at smoking initiation. The association between early age of smoking initiation and
decline in mental HrQOL during menopause was not explained by current smoking
status or by a dose-effect since greater smoking pack-years did not correspond to
decline in MCS. Past smokers who had ceased at age 40 years or older had improved
physical HrQOL and worsened mental HrQOL at year 3 relative to baseline. Little
change was observed in ADLs regardless of smoking status, but current and former
smokers experienced increases in physical activity from baseline to year 3 relative to
never smokers. The most frequently reported menopausal symptoms were joint pain or
stiffness and forgetfulness, regardless of smoking status and time of data collection.
Women who began smoking at younger ages (24 years or younger) experienced more
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menopausal symptoms from baseline to year 3 relative to women who began smoking
aged 25 years or older. Yet women who smoked at least 30 pack-years experienced
fewer menopausal symptoms from baseline to year 3 than women who smoked less
than 10 pack years.
Estimates of prevalence of smoking are much lower in this study than in previous
reports of 40%,13 as only 9% of women reported current smoking and 59% reported that
they had ever smoked. This difference may be due to previous findings that WHI-OS
participants are healthier than the general population. Previous studies have shown
6.3% of all WHI-OS participants at baseline were current smokers.42 Differences in
findings may also be related to the majority of past smokers relative to current smokers.
While previous studies have only linked ever smoking to worsened outcomes in the MS
disease process,13 changes in HrQOL and physical functioning and activity measures
may be strongly related to current smoking than past smoking. For example, our
findings of increased physical activity for current smokers also differ from previous
findings in participants with MS and in the WHI-OS. Previous studies report decreases
in motor function for participants with MS within 10 minutes of smoking a cigarette,43
Studies in the general WHI-OS population also report current smokers were less likely
to engage in more intense physical activity over eight years of followup.44 The small
change in physical activity for current smokers with MS but decline in never smokers
suggests current smokers may compensate for smoking by maintaining physical
activity.
The results of this study show that classifying smoking status as only never, past,
or current use may limit interpretability. Smoking has been linked to increases in MS
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incidence through its alterations to the blood-brain barrier45 by nitric oxide46 and is
affected by ages at smoking initiation and smoking cessation. Younger age at smoking
initiation has been linked to increased risk of MS47 and worsened prognosis from
onset.48 In our study, younger age at smoking initiation was associated with decrease in
mental HrQOL. Women with MS in the WHI-OS who ceased smoking at age 40 years
or older also experienced increases in physical HrQOL but decreases in mental HrQOL
over 3 years. Because ever smokers are more likely to develop progressive disease
faster than never smokers,13 smoking cessation at older ages may be too late to
improve mental HrQOL in post-menopause.
The strengths of this study include the unique population and diverse outcomes
afforded in WHI-OS data. While the WHI was not an MS-only population, efforts were
made during enrollment to represent the general population of post-menopausal
women. Additionally, while no MS-specific measures were collected in the WHI, many
of the outcomes measured in follow-up data (e.g. SF-36 scales, ADLs) are included in
MS-specific composite measures. The WHI-OS also provides data not always present
in other MS registries, such as specific questions regarding menopausal symptoms and
their severities, frequency and duration of smoking (e.g. number of cigarettes per day,
years of smoking before cessation), BMI calculated from physically measured weight
and height, and vitamin D intake from supplements and food.
Some may question the participant-reported physician diagnoses of MS used in
the WHI. A validation study of self-reported diagnosis of MS in the North American
Research Committee on MS registry showed a 98.79% sensitivity of self-report when
compared to chart review and/or physician report.49 The validation subsample
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comprised of 59.8% women with a mean age of 54 years, indicating many of these
women were similar in age to WHI-OS participant and were probably experiencing
menopause or post-menopause at time of study. While no data were available to
ascertain time of MS diagnosis, duration of MS, type of MS, or other disability
measures, we were comfortable with our decision to use self-reported diagnoses.
In summary, this study evaluated the effects of smoking on HrQOL and physical
measures in post-menopausal women with MS. As these women were healthier than
the general population and few were current smokers, effects were not found for all
outcomes by all smoking frequencies or duration. Regardless, women with MS should
be encouraged to quit smoking. Patterns were found pointing to an association
between smoking initiation at younger ages and decline mental HrQOL during
menopause. It is known that smoking increases risk of MS, but longitudinal studies of
age at smoking initiation and outcomes in older age for MS patients are needed.
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Table 2.1. Baseline characteristics of postmenopausal women with multiple sclerosis
(MS) by smoking status in the Women’s Health Initiative Observational Study.
Baseline Characteristics
Years since menopause
Age
<50 – 59 years
60 – 69 years
70 – 79+ years
Race/ethnicity
Non-Hispanic White
Non-Hispanic Black
Hispanic
Other

Current Smoker
(n = 23)

Past Smoker
(n = 126)

Never Smoker
(n = 102)

Median (Standard Deviation)
13.8 (9.4)
11.9 (7.2)
13.2 (8.4)
Percentages
65.2
34.8
0

48.4
40.5
11.1

46.1
37.3
16.7

89.5
10.5
0
0

90.0
6.4
3.6
0

90.5
2.4
3.6
3.6

13.0
47.8
39.1
100

16.0
36.0
48.0
98.4

16.8
36.6
46.5
95.1

8.7
47.8
26.1
17.4

4.8
48.4
26.2
20.6

7.8
42.2
33.3
16.7

0

4.0

17.4
82.6

15.9
80.2

18.6
16.7

34.8
8.7
56.5
100

34.1
18.3
47.6
100

35.3
12.8
52.0
100

16.1
30.1
53.8

12.0
31.0
57.1

N/A
N/A
N/A

52.0
48.0

55.1
44.9

N/A
N/A

< 10

4.3

27.3

N/A

10 to 29

20.2

47.6

N/A

Education
≤ High school
Some college
≥ College graduate
Have any health insurance
Body mass index (kg/m2)
<18.5 (underweight)
18.5 to <25 (normal)
25 to <30 (overweight)
30+ (obese)
Alcohol Use
Never drinker
Past drinker
Current drinker
Menopause Hormone
Therapy
Never User
Past User
Current User
Vitamin D <800 IU per day
Age started smoking (years)
< 20
20 to 24
25 or older
Cigarettes smoked (per day)
< 15
15 or more
Years smoked regularly
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64.7

30 to 49

63.4

23.7

N/A

50 and more

12.0

1.4

N/A

< 10

22.2

44.9

N/A

10 to 29

35.1

31.7

N/A

30 to 49

29.2

14.5

N/A

13.6

8.9

N/A

N/A
N/A
N/A
N/A

1.8
19.2
25.2
53.8

N/A
N/A
N/A
N/A

Pack years

50 or more
Age quit smoking (years)
< 20
20 to 29
30 to 39
40 or older
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Table 2.2. Association between smoking status and change in health related quality of
life measures over 3 years among postmenopausal women with multiple sclerosis (MS)
in the Women’s Health Initiative Observational Study.

Exposure
Smoking history
Never smokers
Ever smokers
Smoking status
Former smokers
Current smokers

Δ Physical Component Score
(3 year-baseline)
β-Coefficient
Adjusted1
Mean Change
(95%
(Standard
Crude
Confidence
Deviation)
Interval)
-0.65 (8.6)

Ref.

-1.10 (9.5)

-0.45

-0.74 (9.1)

-0.10

-2.97 (11.7)

-2.33

-1.25 (9.6)

1.25

-0.58 (9.0)

1.93

-2.51 (12.3)

Ref.

-1.73 (8.3)

Ref.

-0.46 (10.7)

1.27

-1.89 (8.8)

Ref.

-0.12 (11.1)

1.77

-1.65 (8.2)

Ref.

-2.31 (9.0)

-1.49

1.21 (9.9)

2.03

-2.94 (8.9)

Ref.

Ref
-0.58
(-3.1 to 2.0)

Δ Mental Component Score
(3 year-baseline)
β-Coefficient
Mean
Adjusted1
Change
(95%
(Standard
Confidence
Deviation)
Crude
Interval)
-0.84(12.1)

Ref.

0.12 (11.5)

0.96

-0.25 (11.2)

0.59

2.08 (13.4)

2.91

-0.93 (11.4)

-10.03

0.72 (11.2)

-8.37

9.09 (12.4)

Ref.

0.71 (10.3)

Ref.

-0.47 (12.7)

-1.18

Ref.

1.12 (10.6)

Ref.

Ref.

1.80
(-1.5 to 5.1)

-1.89 (13.3)

-3.01

-2.93
(-7.2 to 1.4)

-0.05 (11.2)

Ref.

2.89 (10.1)

3.61

-4.15 (13.9)

-3.43

0.89
(-1.7 to 3.4)
-1.09
(-5.4 to 3.2)

Ref.
0.24
(-3.1 to 3.6)
-0.09
(-3.4 to 3.2)
2.03
(-3.7 to 7.7)

Age started smoking (years)
< 20
20 to 24
25 or older
Cigarettes smoked (per day)
< 15
15 or more
Years smoked regularly
< 30

1.52
(-5.1 to 8.2)
2.15
(-4.9 to 9.2)
Ref.
Ref.
1.60
(-1.5 to 4.7)

30 or more
Number of smoking
pack-years
< 10
10 to 29
30 or more
Age quit smoking (years)
< 40

Ref.
-1.60
(-4.9 to 1.7)
2.30
(-2.8 to 7.4)

-10.50
(-18.9 to -2.1)
-8.81
(-18.1 to 0.4)
Ref.
Ref.
-1.41
(-5.5 to 2.7)

Ref.
3.89
(-0.6 to 8.4)
-3.65
(-10.3 to 3.0)

Ref.
1.79 (10.8)
Ref.
Ref.
3.43
-4.45
0.46 (9.9)
3.38
-2.82 (11.9)
-4.47
40 or older
(-0.3 to 7.2)
(-9.2 to 0.3)
1
Adjusted for the following baseline confounders: years since menopause, alcohol use (current and past
drinking, with referent group as never drinker), and body mass index (<18.5 kg/m as underweight, 25
kg/m2 ≤ BMI < 30 kg/m2 as overweight, and ≥ 30 kg/m2 as obese, with the referent group as 18.5 kg/m2 ≤
BMI < 25 kg/m2, or normal weight).
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Table 2.3. Association between smoking status and change in physical functioning and
activity scores over 3 years among postmenopausal women with multiple sclerosis (MS)
in the Women’s Health Initiative Observational Study.
Δ Activities of Daily Living
(3 year-baseline)

Exposure
Smoking history
Never smokers

Mean
Change
(Standard
Deviation)

β-Coefficient
Adjusted1
(95%
Confidence
Crude
Interval)

0.01 (0.5)

Ref.

-0.02 (0.6)

-0.03

-0.01 (0.53)

-0.02

-0.10 (0.62)

-0.11

0.0 (0.6)

0.25

-0.03 (0.4)

0.22

0.25 (0.5)

Ref.

-0.04 (0.39)

Ref.

0.0 (0.7)

0.04

-0.08 (0.6)

Ref.

30 or more

0.06 (0.5)

0.14

Number of smoking
pack-years
< 10

-0.06 (0.4)

Ref.

10 to 29

-0.02 (0.3)

-0.04

30 or more

-0.27 (1.2)

-0.29

0.01 (0.5)

Ref.

Ever smokers
Smoking status
Former
smokers
Current
smokers
Age started smoking
(years)
< 20
20 to 24
25 or older
Cigarettes smoked (per
day)
< 15
15 or more
Years smoked regularly
< 30

Age quit smoking
(years)
< 40

Ref.
-0.06
(-0.3 to 0.1)

Δ Physical Activity
(3 year-baseline)
Mean
Change
(Standard
Deviation)

β-Coefficient
Adjusted1
(95%
Confidence
Crude
Interval)

-3.66 (12.3)

Ref.

-0.53 (9.8)

3.12

-0.60 (10.2)

3.06

-0.19 (7.0)

3.46

-0.52 (9.3)

-1.70

-0.89 (11.3)

-2.06

1.17 (8.9)

Ref.

Ref.
0.04
(-0.2 to 0.2)

0.14 (11.0)

Ref.

-1.2 (8.4)

-1.33

Ref.
0.14
(-0.1 to 0.3)

0.04 (11.1)

Ref.

-1.07 (6.8)

-1.11

Ref.
-0.05
(-0.2 to 0.1)
-0.30
(-0.7 to 0.1)

-0.84 (9.6)

Ref.

-0.96 (11.8)

2.4

-0.40 (4.6)

1.07

-0.05
(0.2 to 0.1)
-0.14
(-0.3 to 0.1)

0.24
(-0.2 to 0.6)
0.22
(-0.2 to 0.6)
Ref.

Ref.
3.59
(0.8 to 6.3)
3.48
(0.5 to 6.4)
4.15
(-0.8 to 9.1)

-1.43
(-9.3 to 6.4)
-1.75
(-10.2 to 6.7)
Ref.

Ref.
-1.40
(-4.9 to 2.1)
Ref.
-1.04
(-4.8 to 2.7)

Ref.
2.65
(-1.2 to 6.5)
1.25
(-4.8 to 7.3)

Ref.
-0.60 (10.1)
Ref.
Ref.
-0.16
-0.48
40 or older
-0.10 (0.6)
-0.16
-1.09 (8.8)
-0.31
(-0.4 to 0.0)
(-4.6 to 3.6)
1
Adjusted for the following baseline confounders: years since menopause, alcohol use (current and past
drinking, with referent group as never drinker), and body mass index (<18.5 kg/m as underweight, 25
kg/m2 ≤ BMI < 30 kg/m2 as overweight, and ≥ 30 kg/m2 as obese, with the referent group as 18.5 kg/m2 ≤
BMI < 25 kg/m2, or normal weight).
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Table 2.4. Association between smoking status and change in menopausal symptoms
over 3 years among postmenopausal women with multiple sclerosis (MS) in the Women’s
Health Initiative Observational Study.

Exposure
Smoking history
Never smokers
Ever smokers
Smoking status
Former smokers
Current smokers
Age started smoking (years)
< 20
20 to 24
25 or older
Cigarettes smoked (per day)
< 15
15 or more
Years smoked regularly
< 30
30 or more
Number of smoking
pack-years
< 10
10 to 29
30 or more
Age quit smoking (years)
< 40
40 or older

Δ Menopausal Symptoms
(3 year-baseline)
β-Coefficient
Mean Change
(Standard
Adjusted1
Deviation)
Crude
(95% Confidence Interval)
0.01 (3.5)
0.38 (3.5)

Ref.
0.37

Ref.
0.46 (-0.5 to 1.4)

0.37 (3.4)
0.48 (4.1)

0.35
0.47

0.43 (-0.6 to 1.4)
0.61(-1.0 to 2.2)

0.44 (3.7)
0.70 (2.6)
-0.16 (3.5)

2.69
2.95
Ref.

2.94 (0.4 to 5.5)
3.27 (0.5 to 6.0)
Ref.

0.50 (2.9)
0.27 (3.9)

Ref.
-0.23

Ref.
-0.26 (-1.4 to 0.9)

0.08 (3.2)
0.88 (4.1)

Ref.
0.80

Ref.
0.74 (-0.4 to 1.9)

0.35 (3.1)
0.67 (3.1)
-2.13 (4.0)

Ref.
0.0
-2.80

Ref.
-0.1 (-1.3 to 1.1)
-2.75 (-4.7 to -0.8)

0.31 (3.3)
0.35 (3.4)

Ref.
0.12

Ref.
0.06 (-1.3 to 1.4)

1

Adjusted for the following baseline confounders: years since menopause, alcohol use (current and past
drinking, with referent group as never drinker), and body mass index (<18.5 kg/m as underweight, 25
kg/m2 ≤ BMI < 30 kg/m2 as overweight, and ≥ 30 kg/m2 as obese, with the referent group as 18.5 kg/m2 ≤
BMI < 25 kg/m2, or normal weight).
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Chapter 3: Association between Smoking and Health Outcomes in
Postmenopausal Women Living with Multiple Sclerosis
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Abstract
Background: Lowered estrogen levels during the menopausal transition may worsen
quality of life for people living with multiple sclerosis (MS) by further worsening physical
function and symptomology.
Objective: To evaluate the extent to which menopausal hormone treatment (MHT)
improves health outcomes and health-related quality of life (HrQOL) for postmenopausal patients with MS.
Methods: There were 256 women with MS in the Women's Health Initiative
Observation Study with valid information at baseline and year 3. Outcomes included
changes from baseline to 3 years in activities of daily living, physical activity, HrQOL
mental and physical component scales (MCS, PCS) of the SF-36, and menopausal
symptoms.
Results: Fifty-one percent reported current MHT use and 14.8% reported past use.
MHT had no effect on physical functioning, activities of daily living, or menopausal
symptoms. Relative to never MHT users, ever MHT users had higher MCS scores at
year 3 compared to baseline (adjusted β: 3.0, 95% Confidence Interval: 0.4 to 5.6), but
no change in PCS.
Conclusion: Women with MS may experience HrQOL gains with MHT, but its use
must be carefully evaluated in the context of risks and benefits. Contemporaneous data
on MHT use is needed.
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Introduction
Multiple sclerosis (MS) is a progressive disease of the central nervous system
which occurs more often in women than men.50 It is known that patient symptoms
impact quality of life across the lifespan,16 yet it is unknown how menopause may affect
outcomes in MS patients. Menopause (median age of onset 52 years)25 begins a period
of rapid decline in serum estradiol levels in women.51 Fluctuations in estrogen levels are
linked to disease activity in women with MS. Higher estradiol levels during pregnancy
are associated with reduced frequency of relapses, and the precipitous decline in
estradiol levels post-partum is associated with increased frequency of relapses.52
Furthermore, experimental evidence indicates that estrogens have immunomodulatory
and neuroprotective effects, 52 potentially mediating remyelination.53 Therefore, lowered
estrogen levels during the menopausal transition might be expected to worsen MSrelated symptoms and quality of life.
Despite the increasing incidence of MS in women54 and the millions of women
approaching or experiencing menopause32 in the aging population,26 most studies
concerning estrogen and MS have examined women of reproductive ages. Thus,
further examination of outcomes in older women with MS is needed, particularly during
the period of natural decrease in estrogen levels in menopause and beyond. Using a
prospective study of American postmenopausal women, we aimed to evaluate the
extent to which health outcomes and health-related quality of life (HrQOL) improve for
MS patients who have ever used MHT (currently or in the past) compared to neverusing MS patients.
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Methods
Participants
The Women‘s Health Initiative Observation Study (WHI-OS), sponsored by the
National Institutes of Health and the National Heart, Lung, and Blood Institute, is a multicenter study which followed 93,676 racially diverse women ages 50 to 79 years
throughout the U.S.33 Eligible women were post-menopausal, not enrolled in other WHI
clinical trials, and unlikely to relocate or die within 3 years. Protocols for WHI-OS were
reviewed and approved by human subjects review committees at each participating
institution.34 Analyses included 256 WHI-OS participants with MS at baseline who
completed year three assessments by December 2012 and completed questions
regarding MHT. Participants were considered diagnosed with MS if they reported ‘yes’
when answering the question, "Has a doctor ever told you you had MS?"
Determination of MHT use
Self-reported MHT use at baseline was collected in two different ways. WHI
participants were asked to bring in all medications currently used. For those not
currently using MHT, information regarding duration of previous use and type of MHT
used (unopposed estrogen or estrogen-progesterone, in pills or patches) were
collected. These were categorized as MHT history (current, past, or never use),
duration of estrogen-alone or estrogen-progesterone use (<5, 5 to 9, or 10 or more
years), recency of estrogen-alone use (current, past <9, past 10 or more years), and
recency of estrogen-progesterone use (current, past <5, past 5 or more years).
Outcome ascertainment
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We evaluated changes in menopausal symptoms, HrQOL, and indicators of
physical functioning and activity from baseline to year three. Using the Postmenopausal
Estrogen/Progestin Interventions trial40 symptom tool, we considered the following to be
menopausal symptoms: forgetfulness, difficulty concentrating, mood swings, joint pain
or stiffness, headaches or migraines, breast tenderness, increased or decreased
appetite, hot flashes, night sweats, vaginal/genital irritation, and vaginal/genital dryness.
For each symptom, participants were asked how bothersome the symptom was during
the past 4 weeks, with four possible values (0=did not occur, 1=mild, 2=moderate, and
3=severe). We collapsed the response categories for each symptom to a binary
indicator variable (1=present (mild, moderate, or severe), 0=not present). We summed
the number of symptoms present at baseline and at year 3, separately (range 0 to 11).
We treated the outcome as a yes/no indicator of an increase in the number of
symptoms from baseline to year 3 (yes=increase in number of symptoms; no=decrease
or no change).
HrQOL was measured with the RAND 36-Item Health Survey36 using the SF-36
scoring method, which has been validated in the MS population.37 Two summary
scores, the Mental Component (MCS) and Physical Component Scores (PCS), were
calculated from eight subscales (vitality, physical functioning, bodily pain, general health
perceptions, physical role functioning, emotional role functioning, social role functioning,
and mental health). Scores ranged from 0 to 100 points with 50 representing the mean
score in the general population; a score below 50 indicated worse mental or physical
health than the general population. Change scores from year 3 to baseline were
computed, with a positive change score indicating an increase in HrQOL.
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A similar approach was used to evaluate changes in activities of daily living
(ADL) and physical activity. ADLs recorded in the WHI (modified from the original Katz
et al38 index) consisted of four separate items regarding the participant’s ability to eat,
get in and out of bed, dress, and/or take a bath on her own. Each item had three
possible values (1=without help, 2=some help, and 3=completely unable), and scores
were summed (ranging from 4 to 12) to represent overall ADLs with a lower score
indicating better health. The baseline ADL score was subtracted from the year 3 ADL
score such that a positive change score represented a decline in ADLs. Physical
activity was computed from self-reported energy expenditures for recreational activities,
including walking and other mild/moderate/strenuous activity, which are comparable to
physical activity diaries.39 These responses were scored as total metabolic equivalent
tasks (MET)-hours per week. Change scores from year 3 to baseline were computed
with a positive change score indicating an increase in physical activity.
Covariates
Potential confounders included years since menopause, body mass index (BMI),
vitamin D intake, and smoking status. Years since menopause was calculate as the
difference between reported youngest age when menses ceased (age when participant
experienced last menstruation, oophorectomy, or initiated MHT)55 and reported age at
baseline. BMI was calculated in kg/m2 units from heights and weights measured with
calibrated balances and stadiometers. BMI was categorized according to the 2012
World Health Organization guidelines:56 BMI <18.5 kg/m2 as underweight, BMI between
18.5 kg/m2 and less than 25 kg/m2 as normal weight, 25 kg/m2 to less than 30 kg/m2 as
overweight, and at least 30 kg/m2 as obese. Vitamin D intake was recorded using self-
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reported responses to the Food Frequency Questionnaire, which has been validated in
the WHI cohort,57 and questions regarding supplement use. Using previously published
cut points,41 vitamin D insufficiency was defined as <800 IU. Smoking status was
determined from baseline self-report and categorized as current, past, or never smoker.
Statistical analysis
We reported the sociodemographic (age, race/ethnicity, education, health
insurance status), clinical (years since menopause, vitamin D intake, BMI, alcohol use,
smoking history), and MHT use (duration of unopposed estrogen use, recency of
unopposed estrogen use, duration of estrogen-progesterone use, and recency of
estrogen-progesterone use by MHT use. Binary logistic regression models were used
to estimate odds of increased number of menopausal symptoms from baseline to year
3. Confounding was evaluated in an iterative approach. Variables whose addition to
the model resulted in ≥ 10% change in the estimate of association were considered
confounders and retained in the model. We also evaluated fully adjusted models which
included all potential confounders. We also considered reproduction-specific covariates
such as parity and past oral contraceptive use when modeling. As these covariates had
no impact on outcomes evaluated, they were excluded from adjusted models. Odds
ratios and 95% confidence intervals (CI) are provided for both crude and fully adjusted
models.
For continuous outcome variables, multivariable linear regression models were
used to estimate associations between differences in three-year HrQOL, ADL, and
physical activity scores by baseline MHT use. When model building, univariate
distributions of each score difference and years since menopause were examined to
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ensure normality. After examining missing values for determinants and outcomes
conditional on potential confounders, we determined missing data were completely at
random and would not produce biased estimates in these data. Therefore, complete
case analyses were used for each model. Multicollinearity was ruled out by evaluating
correlations between each potential confounder (e.g. years since menopause, BMI,
vitamin D intake, and smoking status). To evaluate confounding, we used the same
iterative approach described above. Model fit was evaluated in several ways. We
visually inspected residual plots to ensure residuals were spaced around zero,
confirming that a linear regression was appropriate for these data. Normality was
confirmed by visually inspecting Q-Q plots for linearity. Outliers were not found when
the studentized residuals were examined. We provided beta coefficients and
corresponding 95% CI from the adjusted models. Statistical significance was
determined using an alpha level of 0.05.
Sensitivity analysis
In a sensitivity analysis, we evaluated the number of women who changed MHT
use from baseline to year 3 measures. Previous studies have shown more than 20% of
women in the WHI-OS reported using MHT for less than 5 years at baseline.42 As MHT
is primarily prescribed to treat vasomotor symptoms25 and these symptoms are usually
strongest within the two years after menopause,51 we predicted some women in this
study would change MHT use status from baseline to year 3. Substantial changes in
MHT use (e.g. occurred in at least 10% of women) would cause exposure
misclassification and would potentially bias our analyses. Therefore we evaluated the
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number of women who reported different MHT status at year 3 and performed the
statistical analyses listed above for this subset.

Results
Among women with MS, 51.2% were current MHT users at baseline and 14.8%
were past users (Table 3.1). More than 20% of past MHT users and 7.6% of current
users were 70 years of age or older. Most current users identified as non-Hispanic
White (93.8%) and 42.8% of non-Hispanic Black participants were ever users. Nearly
52% of current users reported their highest education level as high school diploma or
less, relative to 35.1% of past users who reported the same. An equivalent number of
past or never users were underweight (past users: 10.5%, never: 10.3%) while 2.3% of
current MHT users were underweight. Most current and past MHT users reported
current alcohol use, and 89.7% of current MHT users were ever smokers. All women
had less than 800 IU Vitamin D intake per day from food, over the counter supplements,
and/or prescribed supplements. Higher proportions of current MHT users had
hysterectomies (47.3%) or oophorectomies (33.8%) relative to past users and never
users.
More than one half of ever MHT users had used unopposed estrogen (Table
3.1). Most past MHT users reported using unopposed estrogen for less than 5 years,
while 40.5% of current users of unopposed estrogen had been using MHT for 5 or more
years. Forty-seven percent of past MHT users reported using estrogen and
progesterone for less than 5 years relative to 22.1% of current MHT users reporting the
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same. Nearly 8% of current MHT users had switched between unopposed estrogen
and estrogen and progesterone.
The most common menopausal symptom, regardless of MHT use or time point,
was joint pain or stiffness (Table 3.2). Overall, a similar number of women had
increases in symptoms from baseline to year 3, regardless of MHT use. In particular,
40.5% of current MHT users reported joint pain or stiffness at year 3 relative to 29% at
baseline. After adjusting for years since menopause, smoking status, and BMI, the
odds ratios for increased symptoms at year 3 was 0.81 for current users (95%
Confidence Interval (CI): 0.43 to 1.51) and 0.68 for past users (95% CI: 0.28 to 1.69)
when compared to never users.
Table 3.3 shows the association between MHT use and change in HrQOL from
baseline to year 3 in subjects with MS. Relative to never MHT users, ever MHT users
had a non-statistically significant increase in MCS scores at year 3 compared to
baseline (adjusted β: 3.0, 95% CI: -0.3 to 6.3), but no change in PCS. Never users
experienced an average 1.96 point decline (standard deviation: 10.4) in MCS from
baseline to year 3, whereas women with MS who ever used MHT on average
experienced a 0.63 increase in MCS (standard deviation: 12.3). For women who had
ever used unopposed estrogen, greater increases in HrQOL were shown in MCS rather
than PCS. Women who used unopposed estrogen for less than 5 years had little
change in PCS but higher MCS scores at year 3 compared to baseline (adjusted β:
3.09, 95% CI: -2.0 to 8.2), although not statistically significant. Past users tended to
have higher MCS scores at year 3 compared to baseline compared to never users (<10
years: adjusted β: 3.14, 95% CI: -3.7 to 10.0; 10+ years: adjusted β: 4.18, 95% CI: -3.5
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to 11.8). Interestingly, the effect of MHT use on MCS was not observed for estrogenprogesterone users. For women with MS who had ever used estrogen and
progesterone no changes in MCS scores were apparent. PCS scores were lower at
year 3 than at baseline for women who had used estrogen and progesterone for less
than 5 years (adjusted β: -3.6, 95% CI: -7.5 to -0.3) and past users who ceased 5+
years ago (adjusted β: -6.0, 95% CI: -11.3 to -0.7).
The association between MHT use and change in ADLs and physical activity
from baseline to year 3 are shown in Table 3.4. None of the associations between ADL
change and MHT use were statistically significant. Little change in ADL scores were
observed from baseline to 3 years. The mean ADL change was -0.02 in never MHT
users and -0.01 in ever users. For physical activity, 45.5% of women with MS had
greater than 8 MET-hours/week of physical activity at baseline. The overall patterns
observed indicated that women decreased their activity on average ~2 MET task
hours/week from baseline to year 3. Women who used unopposed estrogen for 10 or
more years maintained their activity levels resulting in a net increase of 2.57 MET task
hours/week from baseline to year 3, compared to never users. None of the associations
between MHT and changes in physical activity were statistically significant.
In our sensitivity analyses, we found 39 women (15.2% of the sample) had
changed MHT status at year 3 assessments (Table 3.5). Most of these women were
never or past users at baseline who began using MHT by year 3 (76.9%), while only 9
women who reported using MHT at baseline stopped at year 3. Similar to all women
included in our sample, this subset was also mostly non-Hispanic White, overweight or
obese, and current alcohol users. Most baseline MHT users stopped using unopposed
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estrogen after less than 9 years duration. As in the general sample, the most common
menopausal symptoms were joint pain or stiffness and forgetfulness (Table 3.6). Unlike
the general sample, at least half of all women who had changed MHT status
experienced increases in symptoms by year 3. Non-significant associations were found
for increased symptoms at year 3 by baseline MHT status.
Directions of associations between baseline MHT status and MCS and PCS for
women who changed MHT use by year 3 were similar to those found in the total
sample, but greater in magnitude (Table 3.7). Ever users at baseline experienced nonstatistically significant decreases in PCS (adjusted β: -3.39, 95% CI: -10.8 to 4.1) and
increases in MCS (adjusted β: 3.0, 95% CI: -0.3 to 6.3) at year 3, relative to never
users. Never users at baseline experienced an average 2.56 point decline (standard
deviation: 8.5) in MCS from baseline to year 3, while ever users at baseline on average
experienced a 3.52 increase in MCS (standard deviation: 16.2). For women who had
ever used unopposed estrogen at baseline, greater increases in HrQOL were shown in
MCS rather than PCS. Women who used unopposed estrogen for less than 9 years
had little change in PCS but higher MCS scores at year 3 compared to baseline
(adjusted β: 12.73, 95% CI: -0.8 to 26.3), although not statistically significant. Past
users tended to have higher MCS scores at year 3 compared to baseline compared to
never users (adjusted β: 11.12, 95% CI: -3.8 to 26.0). For women with MS who had
ever used estrogen and progesterone, decreases in MCS scores were greater in
magnitude than in the total sample. Women who had ever used estrogen-progesterone
at baseline experienced non-significant increases in PCS and decreases in MCS scores
at year 3 compared to baseline. Past users who stopped using MHT less than 5 years
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before baseline had significant decreases in MCS at year 3 (adjusted β: -18.75, 95% CI:
-33.8 to -3.7) compared to never users at baseline.
As in the total sample, no significant associations were found between changes
in limitations due to ADLs and MHT use at baseline for women who changed their MHT
status at year 3 (Table 3.8). Additionally, none of the associations between MHT and
changes in physical activity were statistically significant. Relative to never users, ever
MHT users at baseline maintained their physical activity at year 3. Current users of
unopposed estrogen at baseline increased physical activity at year 3 (adjusted β: 6.16,
95% CI: -7.8 to 19.9) relative to never users, while current users of estrogenprogesterone at baseline experienced no changes. Women who had used estrogenprogesterone for less than 5 years at baseline had fewer decreases in physical activity
relative to never users than women who had used estrogen-progesterone for at least 10
years. Yet women who had used unopposed estrogen for at least 10 years at baseline
had increases in physical activity at year 3 relative to never users (adjusted β: 7.84,
95% CI: -8.0 to 23.7), while women who had used unopposed estrogen for less than 10
years at baseline decreased physical activity at year 3 (adjusted β: -6.69, 95% CI: -18.3
to 4.9).

Conclusions
To our knowledge, this is the first study to estimate the associations between
MHT and outcomes in women living with MS. MHT use was common in women with
MS. In our study, 51% percent reported current use and 14.8% past use. This is
consistent with previous reports of the general WHI population report 45.5% current
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use.42 The extent to which these estimates would be consistent with a contemporary
cohort is unclear as the 2002 results of the WHI clinical trial in estrogen-progestin in
healthy women58 resulted in nationally reduced MHT use.59 In our study, unopposed
estrogen was the most cited choice for managing menopausal symptoms. Additionally,
the women in our study who had stopped using MHT by enrollment in the WHI-OS but
resumed use at year 3 experienced more menopausal symptoms and worse mental
HrQOL than the total sample, indicating that women with MS may be seeking MHT for
relief of symptoms.
The findings regarding HrQOL and MHT among women with MS are intriguing.
Overall, women with MS reporting MHT use had less declines in mental HrQOL
measures (MCS) compared to never users of MHT, suggesting a beneficial effect of
estrogen use on mental health in women with MS during menopause. When evaluating
this finding by type of MHT, we found that for women who had used unopposed
estrogen, greater increases were found in MCS scores than in PCS scores over three
years of follow-up. Yet for women who had used estrogen and progesterone, greater
decreases in PCS scores than in MCS scores were found. Greater changes in MCS
scores are consistent with recent experimental autoimmune encephalomyelitis models,
which suggest that estrogen is protective for synaptic transmission and may improve
memory and cognition in people living with MS.60 Our findings of greater decreases in
PCS than MCS for estrogen-progesterone users differ from other studies in
postmenopausal women with intact uteri. A study in women61 who had used estrogenprogesterone reported non-significant increases in PCS subscales over 9 months, all of
which were below the population norms for Canadian women aged 45 to 54 years.
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Additionally, estrogen-progesterone has been shown to have protective effects62 in
postmenopausal women with cognitive complaints. As most women in our study were
aged 69 years or younger but had used estrogen-progesterone for up to nine years, it is
possible that estrogen-progesterone was not initiated at the youngest appropriate age to
effectively improve mental and physical HrQOL or physical functioning.
Our study found no overall association between MHT and measures of physical
functioning and physical activity. This is consistent with reports from the WHI
randomized trials which also demonstrated no association with self-reported outcomes63,
64

and trials using change in performance-based measures of physical function.65, 66 At

baseline, 45.5% of women with MS had greater than 8 MET-hours/week of physical
activity. This is consistent with previous reports of 55.5% of all women in the WHI-OS
with similar levels of physical activity.42
We found no overall association between MHT and changes in menopausal
symptoms. This is inconsistent with the state of the science report on management of
menopausal symptoms suggests that there is a beneficial effect on some common
symptoms.25 The discrepancy between our study and the literature may be owing to
several reasons. First, because of the limited number of women with MS, we could not
evaluate each individual symptom. Instead we used a composite score which may have
diluted our ability to show benefit of MHT. Second, our data showed a beneficial effect,
but we may not have had sufficient power to demonstrate statistical significance. Third,
in women with MS, the most frequently reported menopausal symptoms were joint pain
or stiffness, regardless of MHT use and time of data collection. This is consistent with
previous findings from the WHI clinical trials and consensus statements which show
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frequent reports of joint pain during menopause, but no clear association between
menopausal status and joint pain.25, 67 Fourth, women with MS may experience fewer
symptoms which are most amenable to MHT intervention. While previous reports of
WHI indicated that vaginal dryness was reported in 27.0% and vaginal irritation or
itching in 18.6% of all women,68 women with MS had lower reports of these symptoms at
baseline.
Strengths of this study include the study population and outcomes evaluated.
The WHI-OS focused on enrollment so that the study participants would represent the
general population of postmenopausal women, particularly those of different
races/ethnicities. Our study population captured women in a more generalizable
community setting, which offers an advantage to other MS studies conducted in clinical
settings. Indeed, the sample size available for this study (n=256) exceeds most singlecenter studies of patients with MS. To our knowledge, only one study20 attempted to
capture menopausal symptoms experienced by women living with MS. This crosssectional study was conducted over twenty years ago and included only 19 postmenopausal women. By evaluating the associations between MHT use and
menopausal symptoms for women with MS in longitudinal WHI data, we were able to
use menopause-specific measures and validated tools for physical functioning, physical
activity, and HrQOL provided by the WHI.
The WHI, however, captured diagnosis of MS using participant-reported
physician diagnoses of MS. No data were available in the WHI-OS to ascertain time of
MS diagnosis, duration of MS, type of MS, or other MS-specific disability measures.
While the WHI did not collect MS-specific measures, MS registries also rely on self-
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reported symptoms and physical function69 and validation studies have shown selfreport is an accurate representation of the MS disease experience.70 In a sample of MS
patients (59.8% female with a mean age of 53.49 years), self-reported diagnoses was
98.79% sensitive when compared to chart review and/or physician report.49
Additionally, while prevalence of MHT use in the WHI was higher than use in
postmenopausal women today,59 the 3-year analysis period in this study reflects current
guidelines for MHT use and is relevant in women living with MS today.71
In summary, this study evaluated the effects of MHT use on HrQOL and physical
measures in post-menopausal women with MS. Consistent with previous research, we
found no overall effect of MHT on physical functioning and activity. However, our
findings show MHT may positively impact mental HrQOL in women with MS, and those
women who are experiencing worse symptoms may seek relief with MHT.25 While more
longitudinal assessments of frequency and duration of MHT use in MS patients are
needed, previous surveys72 have shown nearly 70% of post-menopausal women with
MS do not use MHT for symptom relief. Healthcare professionals should consider
available MHT regimens in the context of efficacy and risk of adverse events when
treating symptoms during menopause and post-menopause.
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Table 3.1. Baseline characteristics of postmenopausal women with multiple sclerosis
(MS) by MHT use in the Women’s Health Initiative Observational Study.
Baseline Characteristics

Years since menopause

Current MHT user
(n = 131)
12.4 (8.3)

Past MHT user
(n = 38)

Median (Standard Deviation)
16.1 (10.6)
Percentages

Never MHT user
(n = 87)
13.6 (8.2)

Age
<50 – 59 years
60 – 69 years
70 – 79+ years
Race/ethnicity
Non-Hispanic White
Non-Hispanic Black
Hispanic
Other
Education
≤ High school
Some college
≥ College graduate
Have any health insurance
Body mass index (kg/m2)
<18.5 (underweight)
18.5 to <25 (normal)
25 to <30 (overweight)
30+ (obese)
Alcohol Use
Never drinker
Past drinker
Current drinker
Smoking History
Never
Past
Current
Vitamin D intake <800 (μg/day)
Ever Hysterectomy
Ever Oophorectomy1
Ever Oral Contraceptive Use
Gravidity
1 to 4 pregnancies
5+ pregnancies
Parity
Never pregnant/term pregnancy
1 to 3 term pregnancies
4+ term pregnancies
MHT type used
Ever unopposed estrogen

56.5
35.9
7.6

47.4
26.3
26.3

37.9
48.3
13.8

93.8
1.8
2.7

89.7
6.9
3.5

85.3
9.3
4.0

1.8

0.0

1.8

51.5
36.2
12.3
98.5

35.1
48.7
16.2
100

43.7
35.6
16.2
94.2

2.3
51.9
29.0
16.8

10.5
44.7
26.3
18.4

10.3
37.9
29.9
21.8

8.4
15.3
76.3

10.5
21.1
68.4

10.3
16.1
73.6

42.1
47.6
10.3
100
47.3
33.8
57.3

34.2
60.5
5.3
100
36.8
23.7
31.6

41.4
49.4
9.2
100
25.3
25.3
44.8

69.5
18.0

78.9
13.2

58.6
27.6

13.7
71.8
14.5

10.5
65.8
23.7

18.4
58.6
23.0

58.8

55.3

N/A
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Ever estrogen-plus-progesterone
Unopposed estrogen duration
< 5 years
5-9 years
10+years
Recency of estrogen-alone use
Current
Past<9 years
Past 10+ years ago
Estrogen-plus-progesterone duration
< 5 years
5-9 years
10+years

41.2

44.7

N/A

18.3
13.0
27.5

34.2
7.9
13.2

N/A
N/A
N/A

51.2
5.3
2.3

N/A
23.7
31.6

N/A
N/A
N/A

22.1
20.6
13.7

47.4
5.3
2.6

N/A
N/A
N/A

48.9
2.3
5.3

N/A
36.8
18.4

N/A
N/A
N/A

Recency of estrogen-plus-progesterone
Current
Past < 5 years
Past 5+ years
1

Includes the removal of one or both ovaries.
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Table 3.2. Association between MHT use and menopausal symptoms at 3 year followup
among post-menopausal women with MS

Menopausal Symptoms

Current MHT user
(n = 131)
Baseline

Year 3

Past MHT user
(n = 38)
Baseline

Year 3

Never MHT user
(n = 87)
Baseline

Year 3

Percentages
Forgetfulness

14.5

14.5

21.1

21.1

17.2

20.7

Difficulty concentrating

10.7

9.9

13.2

13.2

9.2

11.5

Mood swings

9.2

7.6

10.5

10.5

11.5

14.9

Joint pain or stiffness

29.0

40.5

34.2

34.2

29.9

33.3

Headaches or migraines

13.0

10.7

10.5

13.2

12.6

13.8

Breast tenderness

5.3

3.1

2.6

7.9

1.2

2.3

Increased appetite

8.4

7.6

13.2

10.5

10.3

11.5

Decrease appetite

2.3

2.3

0

0

4.6

1.2

Hot flashes

5.3

6.1

7.9

10.5

9.2

2.3

Night sweats

8.4

8.4

10.5

7.9

9.2

9.2

Vaginal/genital irritation

4.6

5.3

2.6

2.6

1.2

2.3

Vaginal/genital dryness
Average number of
symptoms
(Standard Deviation)
Increase in symptoms

3.8

7.6

10.5

18.4

9.2

6.9

1.15
(1.41)

1.24 (1.64)

1.37 (1.79)

1.50
(1.66)

1.25
(1.59)

1.30
(1.64)

24.4

23.7

Crude OR1 (95% CI)

0.85 (0.46 to 1.57)

0.82 (0.34 to 1.97)

Adjusted2 OR (95% CI)

0.81 (0.43 to 1.51)

0.68 (0.28 to 1.69)

27.6
Reference
Reference

1

Here, the outcome evaluated is a yes/no indicator of an increase in the number of symptoms from
baseline to year 3 (yes = an increase in the number of symptoms; no = a decrease or no change), with no
as the referent group.
2

Adjusted for the following baseline confounders: years since menopause, smoking status, alcohol use,
and body mass index (<18.5 kg/m as underweight, 25 kg/m2 ≤ BMI < 30 kg/m2 as overweight, and ≥ 30
kg/m2 as obese, with the referent group as 18.5 kg/m2 ≤ BMI < 25 kg/m2, or normal weight).
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Table 3.3. Association between MHT status and change in health-related quality of life
measures over 3 years among postmenopausal women with multiple sclerosis (MS) in
the Women’s Health Initiative Observational Study.

Exposure
MHT history
Never
Ever

Δ Physical Component Score
(3 year-baseline)
β-Coefficient
Mean
Adjusted1
Change
(95%
(Standard
Crude
Confidence
Deviation)
Interval)
-0.06 (9.2)

Δ Mental Health Component Score
(3 year-baseline)
β-Coefficient
Adjusted1
Mean Change
(95%
(Standard
Crude
Confidence
Deviation)
Interval)
-1.96 (10.4)

-1.36 (9.0)

1.30

< 5 years

-0.83 (10.9)

0.83

5-9 years

-0.33 (8.8)

1.33

10+years

-1.77 (9.2)

-0.11

-1.00 (9.7)

0.66

-2.3 (12.8)

-0.64

-0.53 (6.2)

1.13

< 5 years

-4.44 (9.9)

-4.16

5-9 years

0.05 (7.2)

0.34

10+years

-0.93 (9.4)

-0.64

-1.41
(-4.0 to 1.1)

0.63 (12.3)

2.59

2.71 (12.5)

2.24

0.59 (12.9)

0.12

-0.95 (11.5)

-1.42

-0.10 (13.3)

-0.57

3.04 (7.5)

2.57

1.78 (11.0)

1.31

0.90 (10.5)

0.21

-0.25 (10.7)

-0.94

1.24 (15.8)

0.54

3.00
(-0.3 to 6.3)

Unopposed
estrogen duration
0.17
(-3.8 to 4.1)
0.33
(-4.8 to 5.4)
-1.15
(-5.3 to 3.0)

3.09
(-2.0 to 8.2)
1.09
(-5.6 to 7.8)
-0.36
(-5.8 to 5.1)

Recency of
unopposed
estrogen use
Current
Past <10
years
Past 10+
years ago
Estrogen-plusprogesterone
duration

-0.04
(-3.6 to 3.5)
-0.76
(-6.1 to 4.6)
-0.76
(-6.6 to 5.1)

-3.60
(-7.5 to 0.3)
1.18
(-3.1 to 5.5)
-0.04
(-4.9 to 4.9)

0.55
(-4.0 to 5.1)
3.14
(-3.7 to 10.0)
4.18
(-3.5 to 11.8)

-1.07
(-6.2 to 4.0)
-2.50
(-8.2 to 3.2)
0.06
(-6.5 to 6.4)

Recency of
estrogen-plusprogesterone use
0.52
-1.49
0.49 (11.4)
-0.20
(-3.0 to 4.1)
(-6.2 to 3.2)
Past < 5
-1.80
-2.24
-3.2 (5.7)
-2.95
-0.11 (13.5)
-0.80
years
(-7.1 to 3.5)
(-9.3 to 4.8)
-6.00
0.29
Past 5+ years -7.03 (10.2)
-6.74
1.70 (10.3)
1.01
(-11.3 to -0.7)
(-6.8 to 7.4)
1
Adjusted for the following baseline confounders: years since menopause, alcohol use (current and past
drinking, with referent group as never drinker), and body mass index (<18.5 kg/m as underweight, 25
kg/m2 ≤ BMI < 30 kg/m2 as overweight, and ≥ 30 kg/m2 as obese, with the referent group as 18.5 kg/m2 ≤
BMI < 25 kg/m2, or normal weight).
Current

-0.77 (9.3)

-0.48
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Table 3.4: Association between MHT status and change in physical functioning and
activity scores over 3 years among postmenopausal women with multiple sclerosis (MS)
in the Women’s Health Initiative Observational Study.

Exposure
MHT history
Never
Ever

Δ Activities of Daily Living
(3 year-baseline)
β-Coefficient
Mean
Adjusted1
Change
Crud
(95%
(Standard
e
Confidence
Deviation)
Interval)
-0.02 (0.51)

Δ Physical Activity
(3 year-baseline)
β-Coefficient
Mean
Change
(Standard
Deviation)

Crude

Adjusted1
(95% Confidence
Interval)

-1.84 (10.8)

-0.08

0.51
(-2.4 to 3.5)

-3.22 (11.6)

-0.82

-1.09 (15.6)

1.31

0.01 (10.0)

2.42

-0.52 (12.7)

1.89

-6.23 (13.0)

-3.83

-0.42 (2.4)

1.99

-2.26 (8.9)

-1.79

-3.81 (9.7)

-3.34

-3.24 (8.6)

-2.78

-1.76 (11.2)

-0.01 (0.58)

0.01

< 5 years

-0.03 (0.5)

-0.03

5-9 years

0.00 (0.3)

0.00

10+years

-0.03 (0.3)

-0.03

Current

-0.06 (0.3)

-0.06

Past<9 years

0.06 (0.3)

0.06

0.07 (0.5)

0.07

< 5 years

0.05 (0.6)

0.07

5-9 years

0.0 (0.5)

0.03

10+years

-0.11 (1.1)

-0.08

-0.01
(-0.2 to 0.2)

Unopposed
estrogen duration
0.05
(-0.1 to 0.2)
0.01
(-0.2 to 0.2)
0.00
(-0.2 to 0.2)

-0.90
(-5.4 to 3.6)
1.61
(-4.1 to 7.3)
2.57
(-2.3 to 7.5)

Recency of
unopposed
estrogen use

Past 10+
years ago
Estrogen-plusprogesterone
duration

0.00
(-0.2 to 0.2)
0.08
(-0.3 to 0.5)
0.12
(-0.3 to 0.5)

0.04
(-0.2 to 0.2)
-0.03
(-0.2 to 0.1)
-0.21
(-0.4 to 0.0)

1.85
(-2.1 to 5.8)
-3.61
(-9.7 to 2.5)
1.95
(-4.7 to 8.6)

-1.46
(-5.8 to 2.9)
-3.17
(-8.3 to 1.9)
-2.13
(-7.8 to 3.6)

Recency of
estrogen-plusprogesterone use
-0.07
-3.2
-2.9
-3.67 (10.2)
(-0.6 to 0.1)
(1.9)
(-6.8 to 1.0)
Past < 5
0.16
1.1
1.5
0.19 (0.8)
0.22
0.64 (4.1)
years
(-0.2 to 0.6)
(2.9)
(-4.4 to 7.4)
-0.10
-3.5
-3.2
Past 5+ years
-0.07 (0.3)
-0.04
-3.94 (7.1)
(-0.5 to 0.3)
(3.2)
(-9.5 to 3.1)
1
Adjusted for the following baseline confounders: years since menopause, alcohol use (current and past
drinking, with referent group as never drinker), and body mass index (<18.5 kg/m as underweight, 25
kg/m2 ≤ BMI < 30 kg/m2 as overweight, and ≥ 30 kg/m2 as obese, with the referent group as 18.5 kg/m2 ≤
BMI < 25 kg/m2, or normal weight).
Current

-0.03 (0.7)

-0.01

45

Table 3.5. Baseline characteristics of postmenopausal women with multiple sclerosis
(MS) who changed MHT use status by year 3 in the Women’s Health Initiative
Observational Study.
Baseline Characteristics

Years since menopause

Baseline: Current
Baseline: Past
Baseline: Never
MHT user
MHT user
MHT user
(n = 9)
(n = 13)
(n = 17)
Median (Standard Deviation)
11.8 (9.5)
11.0 (7.8)
12.3 (12.1)
Percentages

Age
<50 – 59 years
60 – 69 years
70 – 79+ years
Non-Hispanic White
Education
≤ Some college
≥ College graduate
Have any health insurance
Body mass index (kg/m2)
<25 (underweight to normal)
25 to <30 (overweight)
30+ (obese)
Alcohol Use
Never drinker
Past drinker
Current drinker
Smoking History
Never
Ever (Current or Past)
Vitamin D intake <800 (μg/day)
Ever Hysterectomy
Ever Oophorectomy1
Ever Oral Contraceptive Use
Gravidity
1 to 4 pregnancies
5+ pregnancies
Parity
Never pregnant/term pregnancy
1 to 3 term pregnancies
4+ term pregnancies
MHT type used
Ever unopposed estrogen
Ever estrogen-plus-progesterone
Unopposed estrogen duration
<10 years
10+years
Recency of estrogen-alone use
Current
Past

66.7
22.2
11.1
100.0

46.2
46.2
7.7
81.8

64.7
17.7
17.7
85.7

33.3
66.7
100.0

50.0
50.0
100.0

58.8
41.2
100.0

44.4
44.4
11.1

46.2
23.1
30.8

35.3
53.0
11.8

0
11.1
88.9

15.4
7.7
76.9

17.7
11.8
70.6

37.5
62.5
100.0
55.6
44.4
44.4

23.1
76.9
100.0
15.4
7.7
30.8

52.9
47.1
100.0
23.5
29.4
47.1

77.8
22.2

69.2
15.4

58.8
35.3

33.3
44.4
22.2

15.4
53.8
30.8

5.9
52.9
41.2

66.7
33.3

23.1
76.9

N/A
N/A

44.4
22.2

15.4
7.7

N/A
N/A

55.6
11.1

N/A
23.1

N/A
N/A
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Estrogen-plus-progesterone duration
< 5 years
5+ years

33.3
11.1

69.2
7.7

N/A
N/A

44.4
0.0

N/A
76.9

N/A
N/A

Recency of estrogen-plus-progesterone
Current
Past
1

Includes the removal of one or both ovaries.
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Table 3.6. Association between MHT use and menopausal symptoms at 3 year followup
among post-menopausal women with MS who changed MHT use status by year 3.

Menopausal Symptoms

Baseline: Current
MHT user
(n = 9)
Baseline

Year 3

Baseline: Past MHT
user
(n = 13)
Baseline

Year 3

Baseline: Never MHT
user
(n = 17)
Baseline

Year 3

Percentages
Forgetfulness

11.1

11.1

30.8

23.1

35.3

35.3

Difficulty concentrating

11.1

0.0

0.0

23.1

5.9

23.5

Mood swings

0.0

0.0

23.1

23.1

5.9

11.8

Joint pain or stiffness

11.1

22.2

38.5

46.2

41.2

35.3

Headaches or migraines

11.1

11.1

23.1

15.4

11.8

23.5

Breast tenderness

0.0

0.0

7.7

15.4

0.0

0.0

Increased appetite

0.0

0.0

23.1

7.7

23.5

17.7

Decrease appetite

0.0

0.0

0.0

0.0

0.0

0.0

Hot flashes

11.1

22.2

15.4

15.4

11.8

5.9

Night sweats

0.0

11.1

15.4

7.7

17.7

11.8

Vaginal/genital irritation

0.0

0.0

7.7

0.0

0.0

0.0

Vaginal/genital dryness
Average number of
symptoms
(Standard Deviation)
Increase in symptoms

0.0

0.0

7.7

7.7

0.0

11.8

0.56
(1.3)

0.78
(1.1)

1.92
(2.4)

1.85
(2.0)

1.53
(1.3)

1.76
(1.8)

50.0

53.9

35.3

Crude OR1 (95% CI)

1.20 (0.21 to 6.80)

0.44 (0.07 to 2.72)

Reference

Adjusted2 OR (95% CI)

1.02 (0.13 to 8.04)

0.37 (0.05 to 2.64)

Reference

1

Here, the outcome evaluated is a yes/no indicator of an increase in the number of symptoms from
baseline to year 3 (yes = an increase in the number of symptoms; no = a decrease or no change), with no
as the referent group.
2

Adjusted for the following baseline confounders: years since menopause, smoking status, alcohol use,
and body mass index (<18.5 kg/m as underweight, 25 kg/m2 ≤ BMI < 30 kg/m2 as overweight, and ≥ 30
kg/m2 as obese, with the referent group as 18.5 kg/m2 ≤ BMI < 25 kg/m2, or normal weight).
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Table 3.7. Association between MHT status and change in health-related quality of life
measures over 3 years among postmenopausal women with multiple sclerosis (MS) who
changed MHT use status by year 3.

Exposure
MHT history
Never
Ever

Δ Physical Component Score
(3 year-baseline)
β-Coefficient
7.ean
Change
Adjusted1
(Standard
Crude
(95% Confidence
Deviation)
Interval)
-0.11 (7.6)

Δ Mental Health Component Score
(3 year-baseline)
β-Coefficient

Crude

Adjusted1
(95% Confidence
Interval)

3.52 (16.2)

4.21

3.89
(-6.3 to 14.1)

10.21 (14.6)

11.29

9.92 (19.2)

11.00

-0.10 (17.5)

13.31

7.22 (14.4)

8.31

-0.05 (16.9)

-11.73

-7.73 (7.7)

-19.42

-2.21 (2.2)

-13.90

Mean Change
(Standard
Deviation)
-2.56 (8.5)

-2.56 (8.5)

-2.45

< 10 years

-1.38 (9.5)

0.88

10+years

-5.16 (18.0)

-2.9

-7.64 (15.4)

-5.39

3.20 (3.3)

5.46

< 5 years

-1.80 (5.8)

2.84

5-9 years

-2.40 (2.4)

2.24

10+years

2.93 (2.9)

2.84

-3.39
(-10.8 to 4.1)

Unopposed
estrogen duration
-0.62
(-12.6 to 11.3)
0.94
(-12.8 to 14.7)

12.73
(-0.8 to 26.3)
1.45
(-14.0 to 16.9)

Recency of
unopposed
estrogen use
Current
Past

-6.87
(-18.8 to 5.1)
6.01
(-5.2 to 17.2)

15.36
(-0.5 to 31.2)
11.12
(-3.8 to 26.0)

Estrogen-plusprogesterone
duration
1.58
(-9.6 to 12.8)
3.90
(-16.1 to 23.9)
5.82
(-15.5 to 27.2)

-9.18
(-23.3 to 4.9)
-22.01
(-3.5 to 47.5)
-12.94
(-40.2 to 14.3)

Recency of
estrogen-plusprogesterone use
7.96
-3.99
1.26 (12.9)
-10.42
(-7.1 to 23.1)
(-22.4 to 14.4)
Past < 5
1.09
-18.75
-2.80 (3.6)
1.84
-5.70 (18.7)
-17.39
years
(-11.3 to 13.4)
(-33.8 to -3.7)
0.97
-4.89
Past 5+ years
-5.90 (2.2)
-1.26
10.03 (3.9)
-1.65
(-14.1 to 16.1)
(-23.3 to 13.5)
1
Adjusted for the following baseline confounders: years since menopause, alcohol use (current and past
drinking, with referent group as never drinker), and body mass index (<18.5 kg/m as underweight, 25
kg/m2 ≤ BMI < 30 kg/m2 as overweight, and ≥ 30 kg/m2 as obese, with the referent group as 18.5 kg/m2 ≤
BMI < 25 kg/m2, or normal weight).
Current

4.32 (8.1)

8.96
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Table 3.8. Association between MHT status and change in physical functioning and
activity scores over 3 years among postmenopausal women with multiple sclerosis (MS)
who changed MHT use status by year 3.

Exposure
MHT history
Never
Ever

Δ Activities of Daily Living
(3 year-baseline)
β-Coefficient
Mean
Adjusted1
Change
Crud
(95%
(Standard
e
Confidence
Deviation)
Interval)
-0.06 (0.4)

Δ Physical Activity
(3 year-baseline)
β-Coefficient
Mean
Change
(Standard
Deviation)

Crude

Adjusted1
(95% Confidence
Interval)

-0.46 (0.5)

-2.21

1.20
(-7.0 to 9.4)

-5.03 (11.1)

-4.01

11.14 (15.4)

12.16

6.92 (13.3)

7.94

-10.44 (13.0)

-9.42

0.0 (0.0)

1.02

-2.18 (8.0)

-5.72

0.0 (0.0)

-3.54

-12.25
(12.25)

-15.79

-1.75 (12.9)

0.0 (0.9)

0.06

< 10 years

-0.40 (0.9)

-0.58

10+years

0.0 (0.0)

-0.18

-0.50 (1.0)

-0.68

0.0 (0.0)

-0.18

0.0 (0.0)

-0.18

< 5 years

0.20 (1.0)

0.49

5-9 years

0.0 (0.0)

0.29

10+years

0.0 (0.0)

0.29

0.21
(-0.2 to 0.6)

Unopposed
estrogen duration
-0.24
(-1.0 to 0.5)
0.32
(-0.5 to 1.1)

-6.69
(-18.3 to 4.9)
7.84
(-8.0 to 23.7)

Recency of
unopposed
estrogen use
Current
Past<9 years
Past 10+
years ago
Estrogen-plusprogesterone
duration

0.22
(-0.6 to 1.0)
-0.32
(-1.1 to 0.5)
0.27
(-1.1 to 1.6)

-0.15
(-0.9 to 0.6)
-0.01
(-1.4 to 1.4)
-0.08
(-1.5 to 1.3)

6.16
(-7.6 to 19.9)
-10.45
(-24.6 to 3.7)
-3.48
(-27.2 to 20.2)

-1.18
(-13.5 to 11.2)
-3.00
(-27.7 to 21.7)
-13.15
(-39.4 to 13.1)

Recency of
estrogen-plusprogesterone use
-0.56
-8.52
0.0 (0.0)
-14.69
(-1.5 to 0.4)
(-25.6 to 8.5)
Past < 5
-0.19
1.40
0.29 (1.3)
0.57
0.78 (3.3)
-2.77
years
(-1.0 to 0.6)
(-11.9 to 14.7)
0.20
-5.98
Past 5+ years
0.0 (0.0)
0.29
-11.15 (10.6)
-3.54
(-0.8 to 1.2)
(-24.2 to 12.2)
1
Adjusted for the following baseline confounders: years since menopause, alcohol use (current and past
drinking, with referent group as never drinker), and body mass index (<18.5 kg/m as underweight, 25
kg/m2 ≤ BMI < 30 kg/m2 as overweight, and ≥ 30 kg/m2 as obese, with the referent group as 18.5 kg/m2 ≤
BMI < 25 kg/m2, or normal weight).
Current

0.0 (0.0)

0.29
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Chapter 4: A Systematic Review of Pharmacological Pain
Management in Multiple Sclerosis
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Abstract
Objective: To systematically review strategies for the reduction of pain in patients with
multiple sclerosis (MS).
Methods: Experimental studies published after 1965 were chosen for review by
searching electronic databases (e.g. PubMed, Cumulative Index to Nursing and Allied
Health Literature, Science Citation Index Expanded, Conference Proceedings Citation
Index- Science, and clinicaltrials.gov) and bibliographies/citations of previously
published reviews. Studies were included if all participants were adults clinically
diagnosed with MS, study sample was not restricted to participants with spasticity or
trigeminal neuralgia, and participant-reported pain was a primary or secondary outcome
measured with a validated tool. Records were screened and methodological qualities of
included studies were assessed independently by two reviewers under the supervision
of another reviewer.
Results: Fifteen studies met the inclusion and exclusion criteria for review; interventions
included antidepressants, anticonvulsants, dextromethorphan/quinidine, cannabinoids,
and opioids/opioid antagonists. Meta-analyses were not performed due to few trials
identified per treatment within these classes. Four trials reported Class 1 evidence.
Pain relief was reported compared to placebo for two of these trials (nabiximols:
Cohen’s d: -0.61; dextromethorphan/quinidine: Cohen’s d: -0.22), but not reported in
two other trials (nortriptyline: Cohen’s d: 0.76; nabixomols: Cohen’s d: 0.93). For these
trials, dizziness was the most commonly reported adverse event, followed by nausea
and somnolence.
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Conclusions: Nabiximols and off-label use of dextromethorphan/quinidine may be
effective in reducing central neuropathic pain in MS. More trials with rigorous design
and reporting are needed to determine effective treatments for specific pain types
presenting in people living with MS.
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Introduction
Multiple sclerosis (MS) is a chronic disease of the central nervous system that
affects nearly 2.5 million people worldwide.1 The health-related quality of life for MS
patients is strongly affected by the disease’s accompanying symptoms.17 Both chronic
and acute pain have been cited as the most common symptoms amongst MS
patients,73-75 with recent prevalence estimates as high as 83%.76 Sources of pain in MS
are difficult to differentiate but certain pain syndromes are common in MS; trigeminal
neuralgia77 presents in 5% and spasticity78 occurs in 50% of MS patients.76 The
evidence for spasticity and trigeminal neuralgia pharmacological treatments in MS has
been systematically reviewed;79-81 yet to our knowledge, no equivalent reviews have
been published concerning MS pain unrelated to these two conditions. Therefore, we
systematically reviewed pain management strategies for the reduction of non-spastic
and non-trigeminal neuralgic pain in MS patients.

Methods
We followed the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guidelines82 for this review. The objective of our search was to
identify all experimental studies published since 1965 (publication year of the first
established MS diagnosis criteria by Schumacher et al)83 which evaluated all pain
management strategies in patients living with MS. Electronic databases, including
PubMed (1965 to November 16, 2012), the Cumulative Index to Nursing and Allied
Health Literature (CINAHL) database (1997 to December 31, 2012), the Science
Citation Index Expanded database and Conference Proceedings Citation Index-
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Science (CPCI-S) database (1965 to December 31, 2012), and clinicaltrials.gov, were
searched for relevant experimental studies. The MEDLINE search strategy in Appendix
was adapted for other databases using the following key words: MS AND pain AND
therapy/management. Additionally, the bibliographies of review articles found during
our queries and the studies citing these reviews were searched to find all available
experimental studies.
Inclusion criteria
Studies were considered eligible for inclusion in this review according to the
following criteria: 1) sample consisted wholly of adult human participants with definite
diagnoses of MS; 2) sample was not restricted to only those with spasticity or only those
with trigeminal neuralgia; 3) patient-reported pain was measured as a primary or
secondary outcome using a previously validated tool; 4) study was published in English
and 5) study involved a pharmacological intervention. Participants were adult humans
aged 18 years or older with clinically diagnosed MS (according to the revised McDonald
criteria3, original McDonald criteria,84 the Poser criteria,85 or the Schumacher criteria83).
Studies were excluded if patient-reported pain was mentioned in the publication as an
adverse event; this avoided the inclusion of disease-modifying therapies whose main
intent was not pain management. Validated tools to measure patient-reported pain
included the visual analogue scale (VAS),86 Patient’s Global Impression of Change
(PGIC),87 McGill Pain Questionnaire (MPQ),88 the Body Pain subscale of the 36-item
Medical Outcome Study Short Form (SF-36),36 and the numerical rating scale
(NRS).89;87
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Because spasticity and trigeminal neuralgia are common in patients living with
MS, a study whose population consisted of a mix of spastic/trigeminal neuralgic patients
and MS patients experiencing other types of pain was considered eligible for inclusion in
this review. Additionally, studies which did not evaluate comparison groups were also
eligible for inclusion to allow for greater scope of review.
Initially we identified 280 records using the search algorithm in Appendix,
including 143 articles from PubMed, 43 articles from CINAHL, 34 articles and records of
conference proceedings in the Web of Science, and 60 records from clinicaltrials.gov
(Figure 4.1). This pool yielded 50 relevant systematic reviews; after searching their
bibliographies and citations, an additional 10 records were eligible for inclusion.
Removing duplicates and screening records by title and abstract reduced the total
number to 64 eligible records, with 15 included in our qualitative synthesis.
Data extraction and synthesis
Articles were independently selected and reviewed by R.J. and S.Y.; when
opinions differed, consensus was reached between R.J., S.Y., and K.L.L. Agreements
between R.J. and S.Y. were strong with a kappa statistic of 0.795. Data extracted
included study type, population characteristics, pain management regimens, and mean
patient-reported pain scores and standard deviations. Study type consisted of parallel
or crossover designs, presence and type of comparison group, mean study duration,
and pain scale used. Population characteristics included mean age, gender, type of
MS, duration of disease, baseline use of pain medications, and baseline disability as
measured by the Extended Disability Status Scale (EDSS).90 Finally, pain management
regimens were evaluated for dose and duration of treatment. For studies which
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evaluated comparator groups, the average duration of treatment for comparison groups
were also recorded. Pain scores were recorded as mean differences between or within
groups weighted by the inverse of the pooled standard deviation (Cohen’s d),91, 92 as this
standardization allowed comparison of effect sizes independent of pain measurement
tools.93 A negative Cohen’s d indicates a relative reduction in pain associated with a
treatment versus a comparator. For studies where the standard deviation was not
reported or incalculable from the reported data, differences between scores were
recorded.
Finally, the methodological qualities of all studies included were examined using
the principles recommended in the Cochrane Handbook for Systematic Review of
Interventions94 and the levels of evidence espoused by the American Academy of
Neurology.95 This included an assessment of the following: randomization sequence
generation, allocation concealment, clear definition of primary outcome,
inclusion/exclusion criteria, and standard treatment for intervention and comparator
groups, and blinding/masking of participants, personnel and outcome assessors. As
this systematic review used previously published data, no ethical approval was sought.

Results
The 15 trials meeting our inclusion an d exclusion criteria are ranked according to
class of evidence in Table 4.1. Seven trials evaluated the intervention with a separate
comparison group while 5 trials used a crossover design and 3 trials were not controlled
(Table 4.2). All except three trials examined participant-reported pain as the primary
outcome. The most common pain scales used were variations of the NRS and VAS; no
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trials used the MPQ but two trials used the Modified Memorial Pain Assessment Card96
and the Brief Pain Inventory short form (BPI-SF),97 respectively. Major classes of
pharmacological interventions included anticonvulsants, antidepressants, cannabinoids,
dextromethorphan/quinidine, and opioids/opioid antagonists. As no more than 3 trials
were identified per pharmacological treatment within these classes, meta-analyses were
not performed. Table 4.3 provides additional information on study design and baseline
characteristics for all included trials.
Anticonvulsants
Six trials evaluated the use of anticonvulsants to treat pain in participants living
with MS; the different types of pharmacological interventions included levetiracetam,98, 99
lamotrigine,100 gabapentin,101 pregabalin,102 and oxcarbamezapine.103 Levetiracetam at a
maximum dose of 3000 mg/day was reported as effective in reducing pain scores when
compared to placebo in both Class 2 and Class 3 trials; this reduction persisted when
measured by the 11-point NRS98 and the 100 mm VAS99 (Cohen’s d: -0.52 and -1.36,
respectively). The most common adverse events for those participants in the treatment
group included tiredness, dizziness and mental changes.
In a Class 3 trial, lamotrigine100 was reported effective in reducing worst and least
pain (Cohen’s d: -0.2 and -0.4, respectively) as measured by the BPI-SF, but ineffective
in reducing average pain in comparison to placebo (Cohen’s d: 0.4); nausea was the
most commonly reported adverse event at a maximum dose of 400 mg/day. Class 4
trials in gabapentin101 (maximum dose of 2400 mg/day) and pregabalin102 (maximum
dose of 300 mg/day) also reported a reduction in pain scores, with adverse events
including mental cloudiness, somnolence, and nausea. Finally, oxcarbamezapine103
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initiated at 150 mg/day and titrated to a maximum dose of 1200 mg/day reduced pain
scores in one Class 4 trial (Cohen’s d: -3.7) with a low rate of adverse events.
Antidepressants
Two trials evaluated antidepressants (nortriptyline and duloxetine) to treat pain in
participants living with MS. While both varied in quality, both studies had similar
inclusion criteria and allowed participants to concurrently use other stabilized pain
medications with the experimental treatment. Nortriptyline,104 when initiated at 10
mg/day and titrated to a maximum dose of 50 mg/day, was not reported to be effective
in comparison to transcutaneous electrical nerve stimulation (TENS; Cohen’s d: 0.76) in
a Class 1 trial. Duloxetine105 was reported to effectively reduce pain scores in
participants of a Class 3 trial of central neuropathic pain (Cohen’s d: -0.44); duloxetine
was initiated at 30 mg/day and titrated to a maximum dose of 60 mg/day. Fewer and
milder adverse events were reported for nortriptyline compared to duloxetine; for both
antidepressants, adverse events included nausea, diarrhea, and somnolence.
Cannabinoids
The two types of cannabinoids assessed were nabixomols, an oromucosal spray
containing 2.7 mg of delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD),
and dronabinol, an oral capsule of 2.5 mg of THC. Two Class 1 trials and one Class 3
trial assessed nabixomols with differing results. A Class 1 trial78 in participants
experiencing central pain reported improvement in pain scores compared to placebo
(Cohen’s d: -0.61); this effect was persistent in the Class 3 trial,106 which also recruited
participants with central pain (Cohen’s d: -0.13). Yet, the other Class 1 trial107 in
nabixomols, which recruited participants experiencing spasticity, spasms, bladder
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problems, tremor, and/or non-musculoskeletal pain, reported no improvement in pain
compared to placebo (Cohen’s d: 0.93). The Class 3 trial in dronabinol108 also reported
improvement in pain scores compared to placebo for participants with central pain
(Cohen’s d: -0.6).
The occurrence of adverse events was similar for all four trials. Dizziness was
the most commonly reported event for any trial, experienced by 20% to 58% of
participants in the intervention groups. Other adverse events included
fatigue/somnolence, vertigo, and headaches. In one Class 1 trial in nabixomols,107
burning at the site of application was reported by 26% of participants in the treatment
group; because 23% of participants receiving placebo also reported this event, the
authors hypothesized this was a result of the ethanol formulation of the oromucosal
sprays. Later studies78, 106 do not report this adverse event, indicating less irritating
formulations may have been created.
Dextromethorphan/Quinidine
One Class 1 trial109 evaluated capsules containing 30 mg dextromethorphan (DM)
and 30 mg quinidine(Q) in participants who had scored at least 13 points on the Center
for Neurologic Study-Liability Scale (CNS-LS) at baseline. While the treatment was
intended for pseudobulbar affect, pain improvement was reported when compared to
placebo (Cohen’s d: -0.22). The most common adverse events reported were nonvertiginous dizziness (26% of participants in the treatment group), nausea (22% of
treatment group), and headache (16% of treatment group).
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Opioids/opioid antagonists
Two trials evaluated an opioid agonist (morphine) and an opioid antagonist
(naltrexone) in separate placebo-controlled crossover studies. A Class 3 trial in
naltrexone110 at 4.5 mg/day reported a reduction in pain scores when compared to
placebo (mean score difference between groups: -2.13). A Class 4 trial in intravenous
morphine111 also reported reduced pain scores compared to a saline placebo (Cohen’s
d: -0.48). Despite the differing effects of each drug, adverse events were similar
between both trials. The most common adverse event was sedation, with vivid
dreaming an added effect of naltrexone.
Quality assessment
Of the 15 trials included in this systematic review, only 4 had Class 1 evidence;
the majority of trials were Class 3 or Class 4 (Table 4.2). One Class 4 trial111 did not
employ randomization when allocating treatments and more than 30% of participants in
one Class 3 trial were lost to attrition and adverse events.100 All controlled trials
employed some blinding or masking methods, but 3 trials did not explicitly blind the
physicians administering or overseeing treatment and 2 did not blind the outcome
assessors. In general, all studies included had poor reporting standards regarding
allocation concealment techniques and compliance differences between treatment and
comparison groups. One Class 3 trial110 noted that 14% of participants were lost due to
poor database management and survey followup.
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Conclusions
Pain is the symptom most commonly reported by people living with MS, yet few
clinical trials have examined interventions for MS chronic pain with little consistency in
treatment mechanisms. To our knowledge, this review is the first to evaluate treatments
for pain unassociated with spasticity and trigeminal neuralgia in MS. Of the studies
identified, the most common classes of drugs studied were anticonvulsants,
antidepressants, cannabinoids, dextromethorphan/quinidine, and opioids/opioid
antagonists.
Our systematic review revealed Class 1 evidence supporting the use of
nabixomols and dextromethorphan/quinidine for pain reduction in MS. While Wade et
al.107 indicated no effect on pain scores due to nabixomols, this may be due to the
inclusion of participants with mixed pain types (including spasticity and nonmusculoskeletal pain). When excluding participants with spasticity, Rog et al78
demonstrated Class 1 evidence for nabixomols reducing pain scores. While nabixomols
are not currently approved for use in the US, it is approved for use in the United
Kingdom where it has been shown to be effective in reducing pain in patients with
MS.112 Additionally, Panitch et al109 demonstrated Class 1 evidence supporting off-label
use of dextromethorphan/quinidine for pain reduction in MS. Currently marketed as
Nuedexta® (20 mg DM/10 mg Q) and approved by the US Food and Drug
Administration for treatment of pseudobulbar affect,113 use of
dextromethorphan/quinidine does not come without risks of QTc interval prolongation,
falls, dizziness, headaches, diarrhea, and interactions with other medications. Indeed,
the risk of ventricular arrhythmias as a result of QTc interval prolongation led to a
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dosage change from 30 mg DM/30 mg Q used by Panitch et al109 to its current market
formulation.114 While the new formulation has not been studied exclusively in MS
patients, a Phase III trial114 in a mixed sample of participants with amyotrophic lateral
sclerosis and MS suggests greater pain improvement and fewer side effects. Careful
clinical consideration of risks and benefits of nabixomols and
dextromethorphan/quinidine are warranted before prescribing. In addition, the cost of
treatment should be considered. Though dextromethorphan/quinidine consists of overthe-counter ingredients, current prices for a month’s supply range from $400 to $600.115
We did not find evidence to support the use of nortriptyline in MS patients
experiencing pain. Nortriptyline has been shown to be very effective in treating
neuropathic pain in other studies,116 yet did not reduce pain scores in the sole trial
presented in this review. This discrepancy may be due to the trial’s protocol of titrating
nortriptyline up to a maximum dose of 50 mg/day,104 while other neuropathic pain trials
have often titrated to much higher doses. If nortriptyline is effective for treating chronic
pain in MS at higher doses, the evidence-base is lacking.
Our review did provide evidence consistent with literature on general neuropathic
pain. In particular, the evidence from Class 2 through 4 trials of gabapentin,117
pregabalin,118 duloxetine,119 intravenous morphine,111 and naltrexone110 are supported by
previous reviews.120, 121 As with Class 1 evidence, some reductions in pain occurred
with treatment, but increases in gastrointestinal and central nervous system adverse
events were non-trivial.
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The strengths of our review lay in our search methodology, inclusion criteria, and
rigorous review methodology. Standardized effect sizes and classification of studies by
methodological and reporting quality are provided to facilitate understanding. Our
inclusion criteria restricting the studies to chronic pain not associated with spasticity or
trigeminal neuralgia allowed is novel. Because such studies in the MS literature are
scarce, we included uncontrolled clinical trials and pilot studies. While the large effect
sizes reported by the uncontrolled studies reflect an overestimation of the true treatment
effect by not accounting for placebo effect, controlled studies are presented separately
from the uncontrolled to aid interpretation. Of the 15 trials presented in this review, only
three did not evaluate patient-reported pain as a primary outcome. The consistent
effect sizes across multiple trials per drug (e.g. levetiracetam, nabixomols) indicate
strength of evidence. While publication bias may be a possibility, our search strategy
was built to minimize this possibility. Our search strategy included studies referenced in
conference proceedings and search clinicaltrials.gov. Indeed, our review included two
Class 1 evidence trials which reported negative effects.
The findings of this systematic review must be considered with a few caveats in
mind. Our review focused on pharmacological management of pain in MS; additional
non-pharmacologic treatments may offer benefits but were beyond the scope of this
review. As evidenced by Chitsaz et al.,104 TENS may be more effective in reducing MS
pain than nortriptyline. Additionally, the relatively small number of trials in MS patients
with chronic pain precludes our ability to make specific recommendations for treatment
strategies. Finally, our review did not reveal any studies of drug combinations. In
studies of general neuropathic pain, drug combinations, such as gabapentin and an
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opioid, are more effective at reducing neuropathic pain than monotherapy.122 Thus, the
extent to which drug combinations would be beneficial in patients with MS is unknown.
In summary, our review identified nabiximols and off-label use of
dextromethorphan/quinidine as promising treatments for chronic pain in MS. Side effect
profiles for both treatments include dizziness, nausea, and headaches, but patients
report acceptable tolerability.114 Unfortunately, generic formulations are not available for
either treatment and nabiximols is not approved for use in the United States. While
nabiximols and off-label use of dextromethorphan/quinidine might be effective, the
evidence base is insufficient to establish how to choose an optimal therapy for particular
patients. In all but one study, the clinical studies were relatively short duration (<4
months). Long term assessment of the efficacy and safety of pharmacologic treatments
of pain in MS patients is needed. In the absence of evidence to help clinicians select
one therapy over another, clinicians and patients must careful consider available
treatment regimens in the context of efficacy, risk of adverse events, cost, and clinical
complexity of the patient (e.g. comorbid conditions and concomitant medication use).
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280 records identified through
database searching

10 additional records identified
through other sources

a

18 duplicates removed

208 records excluded
a

272 records screened by
title and abstract

- 50 review articles
- 159 records did not meet inclusion/exclusion
criteria

49 records excluded
- 28 non-pharmacological interventions
- 5 trials currently ongoing
- 2 articles used the same sample population as
studies already included
- 14 articles did not meet inclusion/exclusion criteria

64 records screened by
full-text for eligibility

15 records included in
qualitative synthesis
a

Sources include the bibliographies and citing articles of the 50 reviews found through database searches.

Figure 4.1. Flow chart of the systematic review.
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Table 4.1. Included trials of pharmacological pain management for multiple sclerosis
(MS) by evidence class and effect size.
Citation

Sample size,
Pain management therapy and dose

Class 1 Evidence
Rog, 2005
N = 66

Pain measurement tool,
Main findings

11-pt NRS
Intervention mean score change (SD): -2.73
(1.9)*
Placebo mean score change (SD): -1.41 (1.7)
Cohen’s d: -0.61

Panitch, 2006

Nabixomols (Oromucosal spray, 5 weeks)
On first day up to 4 sprays delivered in 2
hours (2.7 mg THC/2.5 mg of CBD);
participants advised to increase sprays up to
48 sprays (THC 129.6 mg THC/120 mg CBD)
in 24 hours.
N = 150

Intervention mean score change (SD): -0.4
(0.88)
Placebo mean score change (SD): -0.2 (0.86)
Cohen’s d: -0.22

Chitsaz, 2009

Dextromethorphan/Quinidine (Capsule, 85
days)
Initiated and remained on 30mg DM/30mg Q
every 12 hours throughout duration.
Duration: 85 days
N = 59

Wade, 2004

Nortriptyline (Pill, 8 weeks)
Initiated at 10 mg/day for first 3 days;
increased to 25mg/day for next 4 days;
maximum dose (50 mg/day) continued for
remaining weeks.
N = 160

Intervention mean score change (SD): -1.6
(2.0)
Comparator mean score change (SD): -2.5
(1.6)
Cohen’s d = 0.76
100-mm VAS

5-pt NRS

10-pt VAS

Nabixomols (Oromucosal spray, 6 weeks)
Initiated at 2.7 mg THC/2.5 mg CBD per day
or when necessary; titrated to maximum dose
(120 mg THC/120 mg CBD)
Class 2 Evidence
Rossi, 2009
N = 20

Intervention mean score change: -11.4
Placebo mean score change: -20.17
Pooled SD: 9.4
Cohen’s d: 0.93

Levetiracetam (Tablet, 3 months)
Initiated at 1000 mg/day for week 1; titrated
up to maximum dose (3000 mg/day) at week
4 and continued for remaining weeks
Class 3 Evidence
Falah, 2012
N = 30

Intervention mean score change (SD): -45 (20)
Placebo mean score change (SD): -15 (17)
Cohen’s d: -1.36

NCT0075580
7

100 mm VAS

11-pt NRS

Levetiracetam (Tablet, 6 weeks)
Initiated with 500 mg/day and titrated to
maximum dose (3000 mg/day) for 15 days
N = 239

Intervention mean score change (SD): 5.3 (2.0)
Placebo mean score change (SD): 5.7 (1.8)
Cohen’s d = -0.52
11-pt NRS

Duloxetine (Pill, 6 weeks)
Initiated on 30 mg/day for 1 week; titrated to
60 mg/day for remaining weeks

Group 1 mean score change (SD): -1.83 (1.73)
Group 2 mean score change (SD): -1.07 (1.72)
Cohen’s d: -0.44
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Breuer, 2007

NCT0039107
9

Cree, 2010

Svendsen,
2004

N = 15

BPI Short Form

Lamotrigine (Pill, 13 weeks)
Initiated with 25mg/day for weeks 1 and 2;
increased to 50 mg/day (weeks 3 and 4),
100mg/day (week 5), 200 mg/day (week 6),
300 mg/day (week 7) up tp maximum dose at
week 8 (400 mg/day)
Final dose maintained for 3 weeks then dosetapering occurred for 2 weeks
N = 339

Mean score changes (SD): Worst pain: -1.0
(2.7), Average pain: 0.8 (4.0), Least pain : -0.8
(2.0)

Nabixomols (Oromucosal spray, 14 weeks)
Initiated at 2.7 mg THC/2.5 mg CBD, 8 to 12
sprays per day; titrated to maximum dose
(32.4 mg THC/30 mg CBD)
N = 80

Group 1 mean score change (SD): -2.02 (2.15)
Group 2 mean score change (SD): -1.89 (2.33)
Cohen’s d: -0.13

Naltrexone (Capsule, 8 weeks)
Initiated and continued at 4.5 mg/day

Intervention mean score change: 5.49
Placebo mean score change: 3.36
Difference: -2.13
11-pt NRS

N = 24

Dronabinol (Capsule, 15 to 21 days)
Initiated on 2.5 mg/day, increased 2.5 mg
every other day to maximum dose (10
mg/day)
Class 4 Evidence
Kalman, 2002 N = 14

Cohen’s d:
Worst pain: -0.2
Average pain: 0.4
Least pain: -0.4
11-pt NRS

SF-36 Bodily Pain subscale

Group 1 median score change: -1.0
Group 2 median score change: -1.5
Median difference: −0.6

100 mm VAS

Solaro, 2007

Morphine (Infusion, at least 11 minutes)
Initiated at rate of 1 mg/(kgBWh) until pain
reduction > 50% on VAS; continued at this
maximum dose for 10 min.
N = 12

Intervention mean score change (SD): -21.4
(19.0)
Placebo mean score change (SD): -9.5 (14.7)
Cohen’s d: -0.48
4-pt NRS
Initial mean score (SD): 2.5 (0.5)
Final mean score (SD): 0.2 (0.4)
Cohen’s d: -3.7

Solaro, 2009

Oxcarbamezapine (Pill, 3 months)
Initiated at 150 mg/day and increased every 3
days until achieved pain relief or maximum
dose (1200 mg/day)
N = 16
Pregabalin (Pill, 3 months)
Initiated at 75 mg/day and increased every 3
days until achieved pain relief or maximum
dose (300 mg/day)
N = 25

Initial mean score (SD): 2.4 (0.5)
Final mean score (SD): 0.4 (0.7)
Cohen’s d: -2.3

Gabapentin (Pill, 17 months)
Initiated at 300 mg/day; titrated over 3 weeks
to maximum tolerated dose (ranged from 300
mg/day to 2400 mg/day)

31.8% excellent relief (change of 5 to 9 pts)
36.3% moderate relief (change of 2 to 4 pts)
31.8% no relief (change of 1 to 0 pts)

Houtchens,
1997
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4-pt NRS

Modified Memorial Pain Assessment Card

Table 4.2. Quality Assessment of Included MS Pain Trials.
Treatment
Allocation

Parallel
assignme
nt

Complian
ce or
attrition
unlikely
to
introduce
bias

Comparabl
e Baseline
characteri
stics

Primary
Outcom
e is
Pain

+
+
+
+

+
+
+
+

+
+
+
+

+
+
-

+

+

+

+

+
+
-

?
+
?
+

+
+
+
+
+

+
+
+
+
+

n/a
n/a
n/a

+
+
+
+

+
n/a
n/a
n/a

+
+
+
+

Blinding/Masking

Conceal
Outco
Rando
ed
me
mallocatio Patien Physici Assess
Citation
ization
n
ts
ans
ors
Class 1 Evidence
Rog, 2005
+
+
+
+
+
Panitch, 2006
+
+
+
+
+
Chitsaz, 2009
+
+
+
Wade, 2004
+
+
+
+
+
Class 2 Evidence
Rossi, 2009
+
?
+
Class 3 Evidence
Falah, 2012
+
+
+
+
+
NCT00755807
+
?
+
+
+
Breuer, 2007
+
+
+
+
+
NCT00391079
+
?
+
+
+
Cree, 2010
+
?
+
+
+
Svendsen,
+
+
+
+
+
2004
Class 4 Evidence
Kalman, 2002
?
+
Solaro, 2007
n/a
n/a
n/a
n/a
n/a
Solaro, 2009
n/a
n/a
n/a
n/a
n/a
Houtchens,
n/a
n/a
n/a
n/a
n/a
1997
+ = Yes; - = No; ? = Not reported; N/A = Not Applicable
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Table 4.3. Description of included trials of pharmacological pain management for
multiple sclerosis (MS).
Citation

Location,
Clinicaltrials.gov
ID, Funding
source

Inclusion criteria, Operational definition of
comparison group, Duration of use

Baseline Characteristics

1) Only central pain without a nociceptive cause of
at least 3 months’ duration
2) No spasticity or painless spasms alone or another
non-central pain mechanism
3) No contraindications or comorbidities
4) No cannabinoid use in 7 days prior to screening
5) Concomitant use of stabilized pain medications
allowed

Mean age (SD): 49.2 (8.3) yr
21% men
35% RRMS, 14% PPMS, 50%
SPMS
Mean MS duration (SD): 11.6
(7.7) yr
Mean EDSS score (SD): 5.9
(1.3)

Class 1 Evidence
Rog, 2005

United Kingdom
NCT01604265
Funded by GW
Pharmaceuticals

Panitch, 2006

United States, Israel
Registration status is
unknown
Funded by Avanir
Pharmaceuticals

Chitsaz, 2009

Iran
Registration status
unknown
Funding not reported

Wade, 2004

United Kingdom
NCT01610700
Funded by GW
Pharmaceuticals

Placebo: Oromucosal spray of ethanol:propylene
glycol (50:50)
Duration: 5 weeks
1) On first day of clinic visit, participant scored at
least 13 points on the Center for Neurologic StudyLiability Scale (CNS-LS).
2) No concomitant use of antidepressants,
monoamine oxidase inhibitors, anticoagulants, or
certain other inhibitors or substrates for P450 2D6 or
P450 3A4
3) No contraindications or comorbidities
Placebo: Identical capsules, no other description
given
Duration: 85 days
1) EDSS ≤ 6
2) Natural disease course ≥ 2 years
3) Discontinued use of opioids for duration of study,
but concomitant use of non-opioid pain medication
allowed.
4) No contraindications
Transcutaneous electrical nerve stimulation (TENS):
Self-applied 3 times per day and when needed
Initiated at 60 Hz and 40μs pulses for 20 to 30
minutes; increased to maximum tolerated pulse
strength and continued for remaining weeks
Duration: 8 weeks
1) VAS score at least 50 for one symptom:
spasticity, spasms, bladder problems, tremor, or nonmusculoskeletal pain
2) No contraindications or comorbidities
Placebo: Oromucosal spray of excipients, used daily
and when necessary
Duration: 6 weeks

Class 2 Evidence
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Mean age: 45.0 yr
17.3 % men
Mean MS duration: 10.0 yr

Mean age (SD): 32.4 (7.8) yr
25% men

Mean age (SD): 50.7 (9.3) yr
38.1% men
24% spasticity

Rossi, 2009

Italy
Registration status
is unknown
Funded by Italian MS
Foundation, Italian
Ministries of Health
and Education,
Universities, and
Research, and UCB
Pharmaceuticals

1) Chronic neuropathic pain but not due to
trigeminal neuralgia or other painful manifestations
2) No MS relapse in 30 days prior to randomization
3) No contraindications or comorbidities
4) Concomitant use of stabilized pain medications
not allowed
Placebo: Tablets
Duration: 3 months

Mean age (SD): 37.6 (8.3) yr
25% men
85% RRMS, 5% PPMS, 10%
SPMS
Mean MS duration (SD): 7.2
(5.9) yr
Mean pain duration (SD): 8.2
(5.8) yr
Mean EDSS score (SD): 2.5
(1.3)

Class 3 Evidence
Falah, 2012

Denmark

Inclusion criteria
1) Pain in a body area with sensory abnormality

NCT00423527

on clinical exam/quantitative sensory exam
corresponding to at least one lesion of the central
nervous system
2) Median total pain of at least 4 on an 11-point
scale during 1 week off pain medication before
randomization
3) Concomitant use of stabilized pain medication
not allowed

Not funded, UCB
Pharmaceuticals
sponsored monitoring
throughout trial

Median age: 47 yr
27% men
60 % RRMS, 17% PPMS, 13%
SPMS,
Median MS duration: 8 yr
Median pain duration: 5 yr
Median EDSS score: 5

Washout period: 1 week

NCT00755807

United States,
Belgium, Canada,
and Poland
NCT00755807

Breuer, 2007

Placebo: Tablets
Duration: 6 weeks
1) MS diagnosis at least 1 year prior to study
2) Daily central neuropathic pain due to MS for at
least 3 months prior to study
3) No contraindications or comorbidities
4) Concurrent stabilized pain medication allowed

Funded by Eli Lilly

Placebo: Oral pill taken once daily
Duration: 6 weeks

United States

1) Participant reported MS-related pain with
neuropathic features for at least 3 months and scored
at least 4 for any item on 11-point Neuropathic Pain
Scale
2) No central pain related to other conditions
3) Did not experience 2 or more MS relapses within
the prior 6 months and did not have rapidly
progressive MS
4) Did not receive corticosteroid treatment for MS in
the 30 days prior to screening
5) No contraindications or comorbidities
6) Concomitant stabilized pain medication allowed

Registration status is
unknown
Funded by
GlaxoSmithKline

Washout period: 2 weeks
Placebo: Oral pill taken daily
Duration: 13 weeks
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Mean age (SD): 51.73 (9.4) yr
25% men,
64% RRMS, 11% PPMS, 21%
SPMS,
Mean MS duration (SD): 11.23
(7.99) yr
Mean pain duration (SD): 6.9
(6.3) yr
Mean EDSS score (SD): 4.0
(1.89)
Mean age (SD): 49.3 (11.7) yr
16.7% men

NCT00391079

Canada
NCT00391079
Funded by GW
Pharmaceuticals

1) Central neuropathic pain (CNP) for 3 or more
months and expected to remain stable for the study
duration
2) Baseline pain score sum at least 24
3) Pain not likely to be nociceptive, musculoskeletal
(including spasms) peripheral neuropathic or
psychogenic in origin, or due to trigeminal
neuralgia.
4) No contraindications or comorbidities

Mean age: 49 (10.47) yr
32% men
Mean MS duration (SD): 11.99
(8.26) yr
Mean pain duration (SD): 5.5
(5.5) yr

Placebo: Oromucosal spray of excipients, 8 to 12
sprays per day
Duration: 14 weeks
Cree, 2010

United States

NCT00501696
Funded by private
contributions from
people living with
MS

Svendsen,
2004

Denmark
Registration status
unknown
Funded by Danish
MS Society, private
donations, and Solvay
Pharmaceuticals

1) Did not begin disease-modifying therapy in 3
months prior to enrollment
2) No currently on natalizumab or IFN and/or
glatiramer acetate
2) Not receiving treatment with chronic opiate
agonists

Mean age: 49 yr
30% men,
39% RRMS, 19% PPMS, 16%
SPMS

Washout period: 1 week
Placebo: Capsules taken daily
Duration: 8 weeks
1) Central pain in a body area for abnormal
sensation to pinprick, touch, warmth or cold
(evaluated in person) or quantitative sensory testing
corresponding to at least one lesion in the central
nervous system
2) Pain at maximal pain site with score of at least 3
points on 11-pt NRS
3) No contraindications or comorbidities
4) No marijuana use in 3 months prior to study
5) Concurrent stabilized pain medication allowed

Median age: 50 yr
42% men
38% RRMS, 25% PPMS, 38%
SPMS
Median MS duration: 7.0 yr
Median pain duration: 4.5 yr
Median EDSS score: 6.0

Washout period: 15 to 21 days)
Placebo: Capsules of sesame oil
Duration: 15 to 21 days

Class 4 Evidence
Kalman, 2002

Sweden
Registration status
is unknown
Funded by Country
Council of
Ӧstergӧtland,
Swedish Medical
Research Council
(MFR), The Bank of
Sweden Tercentenary
Foundation, and
Swedish Association
of Neurologically
Disabled

1) Constant, non-fluctuating central pain for at least
6 months
2) 100 mm VAS score > 30 at baseline
3) No trigeminal neuralgia
3) No contraindications or comorbidities
Washout period: 10 min
Placebo: Infusion of physiological saline at a rate of
1 ml/(kgBWh)
Duration: 20 min
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Mean age (SD): 54.9 (11.5) yr
42.8% men,
Mean MS duration (SD): 19.7
(8.8) yr
Mean pain duration (SD): 15.6
(11.7) yr

Solaro, 2007

Italy
Registration status is
unknown
Funding not reported

Solaro, 2009

Italy
Registration status is
unknown
Funding not reported

Houtchens,
1997

United States
Registration status is
unknown
Funding not reported

1) Had painful paroxysmal symptoms (transient pain
in any area with abrupt onset, duration from a few
seconds to a
few minutes, and with repetitive and stereotyped
features)
2) Non-responsive or intolerant to conventional
medications
3) Concomitant use of pain medications not allowed
No comparison group
1) Had painful paroxysmal symptoms (transient pain
in any area with abrupt onset, duration from a few
seconds to a
few minutes, and with repetitive and stereotyped
features)
2) No relapses or worsening greater than 1 point on
the EDSS scale in prior 3 months
3) Previous treatment with conventional medication
for paroxysmal pain
4) No contraindications or comorbidities
5) Concomitant use of neuropathic pain medications
not allowed
No comparison group
1) Attended the MS Clinic at the University of Utah
School of Medicine or Georgetown University MS
Center
2) Concomitant use of pain medications allowed
No comparison group
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Mean age (SD): 43.6 (10.9) yr
31% men,
83% RRMS, 8% PPMS, 8%
SPMS
33% trigeminal neuralgia
Mean MS duration (SD): 7.3
(4.9) yr
Mean EDSS score (SD): 3.8
(1.6)
Mean age (SD): 52 (12.4) yr
38% men,
44% RRMS, 19% PPMS, 38%
SPMS
Mean MS duration (SD): 11.9
(8.0) yr
Mean EDSS score (SD): 5.1
(1.7)

Mean age: 45.8 yr
32% men,
60% RRMS, 32% PPMS, 8%
SPMS
Range of MS duration: 1 to 20
yr
Range of pain duration: 1 to 20
yr

Chapter 5: A Systematic Review of Non-Pharmacological Pain
Management in Multiple Sclerosis
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Abstract
Objective: To systematically review non-pharmacological strategies for the reduction of
pain in patients with multiple sclerosis (MS).
Data Sources: Experimental studies published after 1965 were chosen for review by
searching electronic databases (e.g. PubMed, Cumulative Index to Nursing and Allied
Health Literature, Science Citation Index Expanded, Conference Proceedings Citation
Index- Science, and clinicaltrials.gov) and bibliographies/citations of previously
published reviews.
Study Selection: Studies were included if all participants were adults clinically
diagnosed with MS, study sample was not restricted to participants with spasticity or
trigeminal neuralgia, and participant-reported pain was a primary or secondary outcome
measured with a previously validated tool.
Data Extraction: Records were screened and methodological qualities of included
studies were assessed independently by two reviewers under the supervision of another
reviewer. Pain scores were recorded as mean differences between or within groups
weighted by the inverse of the pooled standard deviation (Cohen’s d).
Data Synthesis: A total of 13 studies which met the inclusion and exclusion criteria
were identified for review; interventions included education, electrical stimulation, and
physical therapies. Meta-analyses were not performed due to few trials identified per
treatment within these classes. Pain relief was reported compared to placebo for two
trials in transcutaneous electrical nerve stimulation (TENS) with effect sizes of -3.37 and
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-3.32, respectively. Inconclusive pain relief was reported for other education and
physical therapies.
Conclusions: TENS may be effective in reducing central neuropathic pain in MS. More
trials with rigorous design and reporting are needed to determine effective treatments
for specific pain types presenting in people living with MS.
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Introduction
Multiple sclerosis (MS) is a chronic disease of the central nervous system that
affects nearly 2.5 million people worldwide.1 The health-related quality of life (HrQOL)
for MS patients is strongly affected by the disease’s accompanying symptoms.17 Both
chronic and acute pain have been cited as the most common symptoms amongst MS
patients,73-75 with recent prevalence estimates as high as 83%.76 Sources of pain in MS
are difficult to differentiate but certain pain syndromes are common in MS; trigeminal
neuralgia77 presents in 5% and spasticity78 occurs in 50% of MS patients.76 The
evidence for spasticity and trigeminal neuralgia treatments in MS has been
systematically reviewed;79-81 yet to our knowledge, no equivalent reviews have been
published concerning MS pain unrelated to these two conditions. In particular, no
reviews have focused on non-pharmacological pain management strategies. Therefore,
we systematically reviewed pain management strategies for the reduction of non-spastic
and non-trigeminal neuralgic pain in MS patients.

Methods
Search Strategy
We followed the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guidelines82 in this review, we identified all experimental studies
published since 1965 (publication year of the first established MS diagnosis criteria by
Schumacher et al)83 which evaluated any pain management strategies in patients living
with MS. Electronic databases were searched, including PubMed (1965 to November
16, 2012), the Cumulative Index to Nursing and Allied Health Literature (CINAHL)
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database (1997 to December 31, 2012), the Science Citation Index Expanded database
and Conference Proceedings Citation Index- Science (CPCI-S) database (1965 to
December 31, 2012), and clinicaltrials.gov.
The MEDLINE search strategy in Appendix was adapted for other databases
using the following key words: MS AND pain AND therapy/management. We searched
the bibliographies of review articles and the studies citing these reviews to find all
available experimental studies.
Inclusion criteria
Studies were considered eligible for inclusion according to the following criteria:
1) sample consisted wholly of adult human participants with definite diagnoses of MS; 2)
sample was not restricted to only those with spasticity or only those with trigeminal
neuralgia; 3) patient-reported pain was measured as a primary or secondary outcome
using a previously validated tool; 4) study was published in English and 5) study
involved a non-pharmacological intervention. Participants were adult humans aged 18
years or older with clinically diagnosed MS (according to the revised McDonald criteria3,
original McDonald criteria,84 the Poser criteria,85 or the Schumacher criteria83). Studies
were excluded if patient-reported pain was mentioned in the publication as an adverse
event; this avoided the inclusion of disease-modifying therapies whose main intent was
not symptomatic pain management. Validated tools to measure patient-reported pain
included the visual analogue scale (VAS),86 McGill Pain Questionnaire (MPQ),88 the
Bodily Pain subscale of the 36-item Medical Outcome Study Short Form (SF-36),36 and
the numerical rating scale (NRS).87, 89 Because spasticity and trigeminal neuralgia are
common in patients living with MS, a study whose population consisted of a mix of
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spastic/trigeminal neuralgic patients and MS patients experiencing other types of pain
was considered eligible for inclusion. Studies which did not evaluate comparison
groups were eligible to allow for greater scope of review.
We identified 280 records using the search algorithm in Appendix, including 143
articles from PubMed, 43 articles from CINAHL, 34 articles and records of conference
proceedings in the Web of Science, and 60 records from clinicaltrials.gov (Figure 5.1).
This pool yielded 50 relevant systematic reviews; after searching their bibliographies
and citations, an additional 10 records were eligible for inclusion. Removing duplicates
and screening records by title and abstract reduced the total number to 64 eligible
records, with 13 included in our qualitative synthesis.
Data extraction and synthesis
Articles were independently selected and reviewed by R.J. and S.Y.; when
opinions differed, consensus was reached between R.J., S.Y., and K.L.L. Agreements
between R.J. and S.Y. were strong with a kappa statistic of 0.795. Data extracted
included study type, population characteristics, pain management regimens, and mean
patient-reported pain scores and standard deviations. Study type consisted of parallel
or crossover designs, presence and type of comparison group, mean study duration,
and pain scale used. Population characteristics included mean age, gender, type of
MS, duration of disease, concomitant use of pain medications or management
strategies, and baseline disability as measured by the Extended Disability Status Scale
(EDSS).90 Finally, pain management regimens were evaluated for type, description,
and duration of treatment. For studies which evaluated comparator groups, the average
duration of treatment for comparison groups were also recorded. Pain scores were
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recorded as mean differences between or within groups weighted by the inverse of the
pooled standard deviation (Cohen’s d),91, 92 as this standardization allowed comparison
of effect sizes independent of pain measurement tools.93 A negative Cohen’s d
indicates a relative reduction in pain associated with a treatment versus a comparator.
However, for the Bodily Pain subscale of the SF-36, a positive Cohen’s d indicates an
improvement in pain-related quality of life or a reduction in pain associated with a
treatment versus a comparator. For these analyses, a Cohen’s d of 0.2 is considered a
small effect, 0.50 a medium effect, and 0.80 a large effect.123 For studies where the
standard deviation was not reported or incalculable from the reported data, differences
between scores were recorded and labeled as such on the tables.
Finally, the methodological qualities of all studies included were examined using
the principles recommended in the Cochrane Handbook for Systematic Review of
Interventions,94 which included an assessment of the following: randomization sequence
generation, allocation concealment, clear definition of primary outcome,
inclusion/exclusion criteria, and standard treatment for intervention and comparator
groups, and blinding/masking of participants, personnel and outcome assessors. As
this systematic review used previously published data, no ethical approval was sought.

Results
The 13 trials meeting our inclusion and exclusion criteria are ranked according to
type of intervention in Table 5.1. Included studies are discussed in greater detail (e.g.
inclusion criteria, baseline characteristics, type of comparison group) in Table 5.2. All
but one trial evaluated an intervention with separate comparison group(s), and the most
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commonly used pain scale was the SF-36 Bodily Pain subscale. Major types of
interventions included education, electrical stimulation, and physical therapy. As no
more than 3 trials were identified per treatment within these groups, meta-analyses
were not performed.
Educational Interventions
Five trials evaluated the use of educational interventions to help manage pain in
participants living with MS; these included energy conservation courses (ECC),124-126
chronic disease self-management courses (CDSMC),127 and hypnosis and/or cognitive
restructuring courses (HCRC).128 ECC, originally meant for fatigue management, had
little124, 126 to no125 improvement in pain-related quality of life, regardless of the presence
of a comparison group. CDSMC was reported as effective in reducing pain scores
when compared to no treatment for participants on the waiting list, but ineffective when
compared to no treatment for patients who did not participate.127 Overall, the greatest
reduction in pain scores was shown for a combination of self-hypnosis and cognitive
restructuring.128
Electrical Stimulation
Two trials129, 130 evaluated transcutaneous electrical nerve stimulation (TENS) in
targeting chronic lower back pain amongst patients with MS. While both studies
measured pain with different scales (MPQ129 and 100 mm VAS130), both reported low
frequency TENS at 4 Hz was more effective at reducing pain scores than high
frequency TENS at 110 Hz.
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Physical Therapy
Of the five trials which evaluated different types of physical therapies, studies
which evaluated outpatient rehabilitation,131-133 yoga and exercise,134 and roboticassisted gait training (RAGT)135 reported the greatest differences in pain scores. The
one trial which evaluated reflexology136 reported no improvement in pain when
compared sham massage. All physical treatments except for reflexology included
educational sessions to address patients’ individualized needs and to teach improved
physical function. Both studies which evaluated directed outpatient rehabilitation
showed improvement in pain-related quality of life compared to waiting list controls131
and self-exercise.132 Additionally, physiotherapy in a warmer climate was shown to be
more effective at reducing pain scores than physiotherapy in a colder climate (Cohen’s
d: -0.12).133 While use of RAGT did not decrease pain scores compared to the walking
control group (Cohen’s d: 0.61),135 the intervention also included healthcareprofessional-directed activities such as strengthening exercises, occupational therapy,
and pool exercises.
Quality assessment
Of the 13 trials included in this systematic review, only one did not evaluate a
comparator group (Table 5.3). Two pilot studies125, 131 did not employ randomization
when allocating treatments and attrition likely introduced bias in two more recent
studies.127, 128 As these studies evaluated non-pharmacological treatments, most
investigators did not adequately blind participants or researchers administering
treatments. Three studies128, 134, 135 did not use intention-to-treat analyses when
evaluating outcomes.
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Conclusions
Pain is commonly reported by people living with MS, yet few clinical trials have
examined interventions for MS chronic pain with consistency in treatment mechanisms.
While pharmacological treatments for pain unassociated with spasticity and trigeminal
neuralgia have been reviewed,137 this is the first review to evaluate non-pharmacological
treatments for chronic pain in MS. There were few studies found and most were of
short duration. Of the identified studies, the most common treatment types were
education, electrical stimulation, and physical therapies.
Of all pharmacological137 and non-pharmacological placebo-controlled trials in
non-spastic and non-trigeminal neuralgic pain, low-frequency TENS (4 Hz, 200 μs) has
the greatest reported reduction in pain scores, regardless of scoring method or duration
of treatment.129, 138 Similar pain reduction has been reported by MS patients with
spasticity139, 140 or using other types of electrical stimulation,141 which suggests TENS
may be effective and cost-effective monotherapy for general MS pain. Yet, TENS has
not been extensively studied in patients with MS and only one trial104 has evaluated pain
relief from TENS relative to a pharmacological agent. Recent reviews142 support the use
of TENS as part of a pain management package instead of monotherapy. Despite this,
Medicare does not cover TENS for patients with MS.143
We did not find conclusive evidence to support the use of other education or
physical therapies in MS patients experiencing pain. However, those therapies which
did not reduce pain scores often improved HrQOL and/or physical function. Two
studies which evaluated outpatient rehabilitation programs reported worsened pain
scores but improvements in SF-36 scores and improved physical function, whether for a
83

duration of 12 weeks132 or one year.131 Yet, mind-body interventions such as hypnosis
and/or cognitive restructuring128 and yoga134 were reported effective in treating pain but
had little to no effect on HrQOL. Similar differences have been found for other MS
patients144 and for cancer-related pain.145 These results suggest clinicians and patients
should also consider overall health when choosing pain management strategies.
The strengths of our review lay in our search methodology, inclusion criteria, and
review methodology. Standardized effect sizes are provided to facilitate understanding.
Because studies in chronic MS pain not associated with spasticity or trigeminal
neuralgia are scarce, we included uncontrolled clinical trials and pilot studies. While
publication bias may be a possibility, our search strategy was built to minimize this by
including studies referenced in conference proceedings and searches in
clinicaltrials.gov. Additionally, the consistent effect sizes across multiple trials per
therapy (e.g. TENS) indicate strength of evidence. The findings of this systematic
review must be considered with a few caveats in mind. Our review focused on nonpharmacological management of pain in MS; additional pharmacologic treatments may
offer benefits137 but were beyond the scope of this review. The relatively small number
of trials in MS patients with chronic pain precludes our ability to make specific
recommendations for treatment strategies.
In summary, our review identified TENS as a promising non-pharmacological
alternative to drug therapy for chronic pain in MS. Clinicians and patients must carefully
consider the risks and benefits of supplanting pharmacological therapy with nonpharmacological therapy such as TENS. The clinical studies were of relatively short
duration (up to one year). Long term assessment of the efficacy and safety of TENS
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and other non-pharmacologic treatments of pain in MS patients is needed. Additionally,
non-pharmacological pain scores are more often measured as a part of HrQOL scales
(e.g. SF-36 Bodily Pain subscore), indicating non-pharmacological interventions are
appropriate for a holistic treatment of neuropathic pain. Thus clinicians and patients
must weigh the importance of using a non-pharmacological therapy solely for pain
management. Physical and educational therapies which do not provide measurable
pain relief may still improve physical function and HrQOL for patients living with MS.
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10 additional records identified

280 records identified through
database searching

through other sources

a

18 duplicates removed

208 records excluded
a

272 records screened by
title and abstract

51 records excluded
- 36 pharmacological interventions
- 1 article used the same sample population as study
already included
- 14 articles did not meet inclusion/exclusion criteria

64 records screened by
full-text for eligibility

13 records included in
qualitative synthesis

a

- 50 review articles
- 159 records did not meet inclusion/exclusion
criteria

Sources include the bibliographies and citing articles of the 50 reviews found through database searches.

Figure 5.1. Flow chart of the systematic review.
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Table 5.1. Included trials of non-pharmacological pain management for multiple sclerosis (MS) by treatment type and effect
size.
Citation

Education
Barlow, 2009

Sample size, Study duration, Operational definition of
pain management therapy

Main findings
Cohen’s d

N = 216
Duration: 4 months

10-pt NRS
CDSMC mean change pain score (SD): -0.2 (2.8)
Waiting List mean change pain score (SD): -0.4 (2.7)
Informed non-attender mean change pain score (SD): -0.3 (2.8)

Chronic Disease Self-Management Course
(2 hr/week for 6 weeks)
Education regarding self-management principles,
communication, and goal setting; delivered by lay
instructors in community settings.
Finlayson, 2005

Cohen’s d:
CDSMC vs. Waiting List: -0.04
CDSMC vs. Informed Non-attender: 0.04
SF-36 Bodily Pain Subscale

N = 29
Duration: 6 sessions

Mean change pain score (SD): 6.9 (25.9)

Jensen, 2010

Energy Conservation Course
(~1 hour/session for 6 sessions)
Fatigue management education regarding living habits and
communication; delivered via teleconference.
N = 22
Duration: 16 hours
Self-Hypnosis Training
(~1 hr/session for 4 sessions)
Clinician-induced hypnosis with suggestions for analgesia
and comfort; participants urged to practice at home.
Cognitive Restructuring
(~1 hr/session for 4 sessions)
Education about role of cognition in pain, coping skills, and
maintenance of skills.
Hypnosis/Cognitive Restructuring
(~1 hr/session for 4 sessions)
Combination of both methods above to reinforce skills and
increase sense of pain control.
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Cohen’s d: 0.27

10-pt NRS
Hypnosis mean change pain score (SD): -0.9 (1.7)
Cognitive mean change pain score (SD): -0.4 (1.9)
Hyp/Cog mean change pain score (SD): -1.58 (1.7)
Education mean change pain score (SD): -0.06 (1.7)
Cohen’s d:
Hypnosis: -0.49
Cognitive: -0.18
Hypnosis/Cognitive: -0.89

Mathiowetz, 2001

Mathiowetz, 2005

N = 54
Duration: 19 weeks

SF-36 Bodily Pain Subscale

Energy Conservation Education
(2 hr sessions/week, 6 weeks)
Fatigue management course regarding living habits and
communication.
N = 169
Duration:12 weeks

Education mean change pain score (SD): -0.6 (23.5)
Control mean change pain score (SD): 4.6 (25.0)
Cohen’s d: -0.19
SF-36 Bodily Pain Subscale
Education mean change pain score: 2.69

Energy Conservation Education
(2 hr sessions/week, 6 weeks)
Fatigue management course regarding living habits and
communication.
Electrical Stimulation
Al-Smadi, 2003
N = 15
Duration:10 weeks

McGill Pain Questionnaire

Low-frequency TENS
(4 Hz, 200 μs)
Applied for 45 minutes 3 times/week for 6 weeks, and as
needed.

Warke 2006

Cohen’s d: 0.18

High-frequency TENS
(110 Hz, 200 μs)
Applied for 45 minutes 3 times/week for 6 weeks, and as
needed.
N = 90
Duration:32 weeks

Low freq TENS mean change pain score (SD): -13.6 (4.1)
High freq TENS mean change pain score (SD): 0.3 (4.1)
Placebo TENS mean change pain score (SD): 0.2 (3.5)
Cohen’s d:
Low freq TENS: -3.37
High freq TENS: 0.02

100 mm VAS
Low freq TENS mean change pain score: -20.76
Hgh freq TENS mean change pain score: -8.21
Placebo TENS mean change pain score: -17.44

Low-frequency TENS
(4 Hz, 200 μs for 45 minutes)
Applied twice daily for 6 weeks and as needed.

Mean Difference:
Low freq TENS: -3.32
High freq TENS: 9.23

High-frequency TENS
(110 Hz, 200 μs for 45 minutes)
Applied twice daily for 6 weeks and as needed.
Physical Therapy
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Di Fabio, 1997

Hughes, 2009

Oken, 2004

N = 31
Duration: 1 year

SF-36 Bodily Pain Subscale

Outpatient Rehabilitation
(5 hours/day, 1 day/week)
Physical and occupational therapy, structured recreational
experiences, and counseling.
N = 71
Duration: 10 weeks
Reflexology
(45 min/week)
Pressure massage sequences stimulating key reflex points
on feet associated with pain throughout body.
N = 69
Duration: 6 months
Yoga Sessions
(90 min/week)
Iyengar yoga with 19 instructed poses; held for up to 30
sec with 30 sec to 1 min rest period between; all poses
supported by chair or leaning against wall.

Patti, 2002

Aerobic Exercise Sessions
(1 class/week and home exercise)
Recumbent/stationary bicycling or using a Swiss ball; kept
moderate pace (participants able to converse while
exercising) until stopped due to fatigue/exacerbated
symptoms/reached 1 hour.
N = 111
Duration: 12 weeks
Outpatient Rehabilitation
(50 to 60 min/day, 6 days/week)
First 6 weeks were instruction; next 6 weeks were selfexecuted physiotherapy, occupational therapy, speech
therapy, group therapy, and other personalized therapy.
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Outpatient Rehabilitation effect size: 0.16
Waiting List Control effect size: -0.03
Effect size difference: 0.19
10 mm VAS
Reflexology median pain score difference: 3
Placebo median pain score difference: 3
Median value difference: 0
SF-36 Bodily Pain Subscale
Yoga mean change pain score (SD): -1.4 (18.6)
Exercise mean change pain score (SD): 15.7 (15.5)
Control mean change pain score (SD): 3.8 (25.7)
Cohen’s d:
Yoga: -0.22
Exercise: 0.87

SF-36 Bodily Pain Subscale
Rehabilitation mean change pain score (SD): 14.9 (20.0)
Self-exercise mean change pain score (SD): -0.1 (0.6)
Cohen’s d: 0.91

Smedal, 2010

Vaney, 2012

N = 60
Duration: 18 months

10-pt NRS

Physiotherapy in Hakadal, Norway
(60 min/day, 4 weeks)
Physiotherapy focused on improving patient’s own
movement control; measurements taken after 6 months of
followup.
N = 67
Duration: 3 weeks
Robotic-Assisted Gait Training
(30 min/session, 9 sessions)
Support began at 50% of body weight then reduced after
observing gait pattern; also included strengthening
exercises, horseback riding, pool exercises and
occupational therapy.
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Norway mean change pain score (SD): 0.5 (2.6)
Spain mean change pain score (SD): 0.2 (2.7)
Cohen’s d:
Spain vs. Norway: -0.12
10 mm VAS
RAGT mean change pain score (SD): 1.0 (2.68)
Walking group mean change pain score (SD): -0.70 (2.91)
Cohen’s d: 0.61

Table 5.2. Description of included trials of pharmacological pain management for multiple sclerosis (MS).
Citation

Education
Barlow,
2009

Location,
Registration
ID, Funding

Inclusion criteria, Study type, Operational definition of comparison
group

Baseline Characteristics

United
Kingdom

Inclusion criteria
1) Able to understand and participate in English

Mean age (SD): 51.1 (11.1) yr
27.3% men,
Mean MS duration (SD): 12 (9.3) yr

Registration
status unknown

Parallel assignment

Funded by UK
MS Society

Finlayson,
2005

USA
NCT00591721

Jensen,
2010

Funded by
University of
Illinois
USA
NCT00621374
Funding
information not
provided

Waiting List Controls
Included those on waiting list
Informed Non-Attenders
Aware of research and course, yet indicated they did not want to attend
Inclusion criteria
1) Fatigue Severity Scale score ≥ 4
2) No cognitive impairments according to Blessed Orientation Memory
Concentration test

Mean age (SD): 47 (9.6) yr
17.2% men,
62.1% RRMS, 3.4% PPMS, 17.2% SPMS,
Mean MS duration (SD): 9.8 (5.1) yr
Mean symptom duration (SD): 14 (6.7) yr

Uncontrolled
Inclusion criteria
1) 10-pt NRS chronic pain score ≥ 4 for at least 6 months
2) Telephone Interview of Cognitive Status score > 20
3) In counseling/psychotherapy ≤ 1 session/week
4) No psychiatric hospitalizations, hypnosis, cognitive behavioral therapy,
or active suicidal ideation in past 6 months
Crossover
Education Control
(~1 hr/session for 4 sessions)
Education on scope of pain in MS patients and management strategies;
specific coping skills not taught.
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Mean age: 52.6 yr
20% men

Mathiowet
z, 2001
.

USA,
Registration
status unknown
Funding
information not
provided

Mathiowet
z, 2005

USA
Registration
status unknown
Funding
information not
provided

Electrical Stimulation
Al-Smadi,
Northern
2003
Ireland
Registration
status unknown
Funding
information not
provided

Inclusion criteria
1) Fatigue Severity Scale score ≥ 4
2) Community dwelling
3) Received personal care or homemaker services ≤ 10 hrs/week
4) Not in other rehabilitation programs
5) Stabilized concomitant fatigue treatments allowed

Mean age (range): 50 (31 to 74) yr
33% men,
36% RRMS, 22% PPMS, 13% SPMS,
Mean MS duration (range): 9.5 (1 to 34) yr

Crossover
Duration of washout period: 6 weeks
Control Support Group
(2 hr sessions/week, 6 weeks)
Discussed living with MS with no mention of fatigue management
Inclusion criteria
1) Fatigue Severity Scale score ≥ 4
2) Community dwelling
3) Passed 3 of 4 subsets of Neuropsychological Screening Battery for MS

Mean age (SD): 48.3 (8.4) yr
17.2% men,
61.5% RRMS, 5.9% PPMS, 18.9% SPMS,
Mean MS duration (SD): 9.5 (7.4) yr
Mean symptom duration (SD): 14.9 (9.7) yr

Crossover
Control Period
(6 weeks)
No intervention, so washout period not used.

Inclusion criteria
1) Chronic lower back pain for ≥ 3 months
2) No contraindications to transcutaneous electrical nerve stimulation
(TENS), analgesic abuse, or sacral pressure ulcers
3) Stabilized concomitant pain treatments
Parallel assignment
Placebo TENS
Used same machinery with no frequency
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No information provided

Warke
2006

Northern
Ireland
Registration
status unknown
Funded by the
MS Society of
Great Britain
and Northern
Ireland

Physical Therapy
Di Fabio,
USA
1997
Registration
status unknown

Inclusion criteria
1) Chronic lower back pain for ≥ 3 months
2) No contraindications to transcutaneous electrical nerve stimulation
(TENS), analgesic abuse, or sacral pressure ulcers
3) Stabilized concomitant pain treatments allowed

Mean age: 47.4 yr
23.3% men,
Mean MS duration: 10.7 yr
Mean pain duration: 10.4 yr

Parallel assignment
Placebo TENS
Used same machinery with no frequency

Inclusion criteria
1) Progressive MS course
2) EDSS score between 5 and 8

Mean age: 47.4 yr
19.4% men,
Mean MS duration: 15.5 yr

Parallel assignment

Hughes,
2009

Funding
information not
provided
Northern
Ireland
Registration
status unknown

Waiting List Control
On waiting list for treatment, not receiving outpatient rehabilitation
Inclusion criteria
1) EDSS score ≤ 7.5
2) Pain VAS score > 4
3) No previous experience with reflexology
Parallel assignment

Funded by U.S.
National
Multiple
Sclerosis
Society

Placebo
(45 min/week)
Standardized foot massage with same sequence as treatment, but
avoided key reflex points.
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Mean age: 51.5 yr
16.9% men,
39.4% RRMS, 11.3% PPMS, 26.8% SPMS,
Mean MS duration: 12.5 yr
Mean EDSS score: 6.0

Oken,
2004

USA
Registration
status unknown
Funding
information not
provided

Inclusion criteria
1) EDSS score < 6.0
2) No comorbidities or cognition impairment
3) Did not perform yoga/tai chi in past 6 months
4) Did not regularly perform aerobic exercise for > 30 min/day

Mean age: 49.0 yr
5.8% men,
Mean EDSS score: 2.0

Parallel assignment
Waiting List Controls
Received no intervention.

Patti,
2002

Italy
Registration
status unknown
Funding
information not
provided

Inclusion criteria
1) EDSS score between 4.0 and 8.0
2) Mini-Mental State Exam score > 24
3) No comorbidities or contraindications
4) No rehabilitation, MS disease-modifying drugs, or other experimental
drugs 6 months prior to study

Mean age: 45.6 yr
42.3% men,
Mean MS duration: 17.2 yr
Mean EDSS score: 6.2

Parallel assignment
Self-exercise Program
Control group performed self-exercise program at home for 12 weeks.

Smedal,
2010

Norway and
Spain
NCT01057719
Funded by
Oslo University
Hospital,
Haukeland
University
Hospital, and
Western
Regional
Health
Authority

Inclusion criteria
1) EDSS score of 4.0 to 6.5
2) No past experiences with heat intolerance or excessive fatigue
3) Non-severe cognitive dysfunction
4) No comorbidities
Crossover
Washout period duration: 6 months
Physiotherapy in Tenerife, Spain
(60 min/day, 4 weeks)
Physiotherapy focused on improving patient’s own movement control;
measurements taken after 6 months of followup.
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Mean age (SD): 48.5 (9.0) yr
40% men,
63.3% RRMS, 5% PPMS, 31.7% SPMS,
Mean EDSS score (SD): 4.5 (1.5)

Vaney,
2012

Switzerland
Registered in
Switzerland:
ISRCTN69803
702
Funded by
Berner Klinik
Montana,
ReSAR/HESSO of
Switzerland

Inclusion criteria
1) EDSS score between 3.0 and 6.5
2) Able to walk 14 meters with or without assistive devices
3) Non-severe osteoporosis or scoliosis
4) Even leg lengths
5) No comorbidities
Parallel assignment
Walking Group
(30 min/session, 9 sessions)
Walked in a group with physiotherapist, in gym, or on uneven ground
outdoors.
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Mean age: 56.3 yr
Mean EDSS score: 5.8

Table 5.3. Quality Assessment of Included MS Pain Trials.
Treatment
Allocation
Randomizat
ion
Citation

Blinded
allocati
on

Blinding
Patien
ts

Physicia
ns

Outcom
e
Assesso
rs

Barlow,
+
+
?
2009
Finlayson
N/A
N/A
N/A
N/A
N/A
, 2005
Jensen,
+
?
?
?
+
2010
Mathiowe
?
?
?
?
tz, 2001
Mathiowe
+
?
?
tz, 2005
Al-Smadi,
+
+
+
+
2003
Warke
+
+
+
+
2006
Di Fabio,
N/A
?
1997
Hughes,
+
+
+
+
2009
Oken,
+
+
+
2004
Patti,
+
+
+
+
+
2002
Smedal,
+
?
2010
Vaney,
+
+
2012
+ : Present; - : Not Present; ? : Not Reported; N/A : Not Applicable

Comparis
on group

Primar
y
Outco
me as
Pain

Complian
ce
unlikely
to
introduce
bias

Attritio
n
unlikely
to
introdu
ce bias

Compara
ble
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Intenti
on to
Treat
Analys
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+
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+

+
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-

-
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Appendix
MEDLINE search strategy

(1965/01/01:2012/11/16[dp]) AND (Clinical Trial[pt] OR Randomized Controlled Trial[pt]
OR Controlled Clinical Trial[pt] OR trial*[all] OR intervention*[all]) AND (((multiple
sclerosis[majr]) OR ("multiple sclerosis"[tiab]) OR multiple sclerosis[all]) NOT (trigeminal
neuralgia[mh]) NOT (muscle spasticity[mh])) AND (pain[majr] OR “pain”[tiab] OR
(pain[mh] NOT chemically induced[sh]) OR (pain management[mh] OR pain
measurement[mh]))

1

Filters for human- and English-only studies were not applied in this algorithm to capture all available

articles in the database, including newer, non-indexed articles. Articles were later screened to exclude
non-human studies (0 articles found) and non-English publications (14 articles found).
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